CLINICAL STUDY PROTOCOL  
NCT Number:  
Study Title:  
Study Number:  NCT04
056468 
Phase 1 Pharmacokinetics and Safety Study of Oral Mobocertinib in 
Subjects With Moderate or Severe Hepatic Impairment and Normal Hepatic Function 
TAK-788- 10
08
Protocol Version and Date: 
Ve
rsion 2.0: 12-Aug-2 020 
TITLE PAGE
TAKEDA PHARMACEUTICALS
PROTOCOL
Phase 1 Pharmacokinetics and Safety Study of Oral Mobocertinib in Subjects with 
Moderate or Severe Hepatic Impairment and Normal Hepatic Function
Study Identifier: TAK-788-1008
Compound: Mobocertinib
Date: 07August 2020
Version/Amendment 
Number:Amendment 2
Amendment History : 
Date Amendment Number Amendment Type Region
12 July  2019 Initial Version Not applicable United States
10 September 2019 01 Appendix E United States
07August 2020 02 Appendix F United States
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Mobocertinib
Study No. TAK -788-1008 Page 2of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALTABLE OF CONTENTS
1.0 STUDY SUMMARY ...................................................................................................... 7
2.0 STUDY SCHEMATIC .................................................................................................. 14
3.0 SCHEDULE OF STUDY PR OCEDURES .................................................................... 15
4.0 INTRODUCTION ......................................................................................................... 19
4.1 Background ............................................................................................................. 19
4.2 Rationale for the Proposed Study ............................................................................. 20
4.3 Child -Pugh Cl assificat ion of Hepat ic Impairment .................................................... 21
4.4 Benefit/Risk Profile .................................................................................................23
5.0 STUDY OBJECTIVES AND ENDPOINTS .................................................................. 24
5.1 Hypothesis ............................................................................................................... 24
5.2 Study  Objectives ...................................................................................................... 24
5.2.1 Study  Primary  Object ive............................................................................. 24
5.2.2 Study  Secondary  Object ives........................................................................ 24
5.2.3 Study  Expl oratory  Object ive....................................................................... 24
5.3 Endpoints ................................................................................................................. 24
5.3.1 Primary Endpo int........................................................................................ 24
5.3.2 Seco ndary  Endpo ints................................................................................... 25
5.3.3 Exploratory  Endpo int.................................................................................. 25
6.0 STUDY DESIGN AND DES CRIPTION ....................................................................... 26
6.1 Study Design ........................................................................................................... 26
6.2 Dose Escal ation....................................................................................................... 27
6.3 Rationale for Study Design, Dose, and Endpoints .................................................... 28
6.3.1 Rationale of Study Design ........................................................................... 28
6.3.2 Rationale for Dose ...................................................................................... 28
6.3.3 Rationale for Endpoints ............................................................................... 28
6.3.3.1 Pharmacokinet ic Endpo ints.................................................................... 28
6.3.3.2 Safety Endpo ints.................................................................................... 29
6.3.4 Future Bio medical Research ........................................................................ 29
6.3.5 Critical Procedures Based on Study  Object ives: Timing of Procedures ........ 29
6.4 Study  Design/Dosing/Procedures Modificat ions Permitted Within Protocol 
Param eters ............................................................................................................... 29
6.5 Study  Beginning and End/Co mpletion..................................................................... 29
6.5.1 Definit ion of Beginning o f the Study........................................................... 29
6.5.2 Definit ion of End of the Study ..................................................................... 30
6.5.3 Definit ion of Study  Com pletion.................................................................. 30
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Mobocertinib
Study No. TAK -788-1008 Page 3of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIAL6.5.4 Definit ion of Study  Discont inuat ion............................................................ 30
6.5.5 Criteria for Premature Terminat ion or Suspension of the Study ................... 30
6.5.6 Criteria for Premature Terminat ion or Suspension of a Site ......................... 30
7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS .............. 31
7.1 Inclusio n Cri teria..................................................................................................... 31
7.1.1 Inclusio n Cri teria for Heal thy Subjects ........................................................ 31
7.1.2 Inclusio n Cri teria for Subj ects wi th Moderate or Severe Hepat ic 
Impairment.................................................................................................. 32
7.2 Exclusio n Cri teria.................................................................................................... 33
7.2.1 Exclusio n Cri teria for Heal thy Subjects ....................................................... 33
7.2.2 Exclusio n Cri teria for Subj ects wi th Moderate or Severe Hepat ic 
Impairments................................................................................................ 34
7.3 Prior and Concomi tant Medicat ions and Therapies ................................................... 35
7.4 Excluded Medicat ions, Supplements, Dietary  Products ............................................ 36
7.5 Diet, Fl uid, Act ivity.................................................................................................37
7.5.1 Diet and Fluid ............................................................................................. 37
7.5.2 Activity....................................................................................................... 37
7.6 Criteria for D iscontinuation or Withdrawal o f a Subject ........................................... 38
7.7 Procedures for Discont inuat ion or Withdrawal o f a Subject ...................................... 38
7.8 Subject Replacement ................................................................................................ 38
8.0 CLINICAL STUDY MATER IAL MANAGEMENT ..................................................... 39
8.1 Clinical Study Drug .................................................................................................39
8.1.1 Clinical Study Drug Labeling ...................................................................... 39
8.1.2 Clinical Study Drug Inventory  and Storage ................................................. 39
8.1.3 Clinical Study Drug Blinding ...................................................................... 39
8.1.4 Randomization Code Creation and Storage ................................................. 39
8.1.5 Clinical Study  Blind Maintenance/Unblinding Procedure ............................ 40
8.1.6 Accountabilit y and Destruction of Sponsor -Supplied Drugs ........................ 40
9.0 STUDY PROCEDURES ............................................................................................... 41
9.1 Administrative Procedures ....................................................................................... 41
9.1.1 Inform ed Consent Procedure ....................................................................... 41
9.1.1.1 Assignment of Screening and Allo cation Numbers .................................41
9.1.1.2 Study  Drug Assignment .......................................................................... 41
9.1.2 Inclusio n and Exclusio n.............................................................................. 41
9.1.3 Medical History /Dem ography ..................................................................... 41
9.1.4 Concomitant Medications ............................................................................ 41
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Mobocertinib
Study No. TAK -788-1008 Page 4of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIAL9.2 Clinical Procedures and Assessments ....................................................................... 41
9.2.1 Full Physical Examinat ion........................................................................... 42
9.2.2 Height and Wei ght...................................................................................... 42
9.2.3 Body  Mass Index ........................................................................................ 42
9.2.4 Vital Signs .................................................................................................. 42
9.2.5 12-Lead EC G................................ .............................................................. 42
9.2.6 Pulmo nary Function Test ............................................................................ 43
9.2.6.1 Spirometry.............................................................................................. 43
9.2.7 Study Drug Administration ......................................................................... 43
9.2.8 AE Monitoring ............................................................................................ 43
9.2.9 Laboratory  Procedures and Assessments ..................................................... 43
9.2.9.1 Clinical Laboratory  Tests ........................................................................ 44
9.3 Pharmacokinet ic Samples ........................................................................................ 45
9.3.1 PK Measurements ....................................................................................... 45
9.3.1.1 Plasma PK Measurements ...................................................................... 45
9.3.2 47
9.3.3 PGx Measurements ..................................................................................... 47
9.3.4 Confinement ............................................................................................... 47
10.0 ADVERSE EVENTS .................................................................................................... 48
10.1 Definit ions and El ements of AEs ............................................................................. 48
10.1.1 SAEs ........................................................................................................... 50
10.1.2 Speci al Interest AEs .................................................................................... 51
10.2 AE Procedures ......................................................................................................... 51
10.2.1 Assigning Severit y/Intensit y of AEs ............................................................ 51
10.2.2 Assigning Causalit y of AEs ......................................................................... 52
10.2.3 Start Date .................................................................................................... 52
10.2.4 End Date ..................................................................................................... 52
10.2.5 Outcom e..................................................................................................... 52
10.2.6 Collect ion and Reporti ng of AEs, SAEs, Special Interest AEs, and 
Abnorm al LFTs ........................................................................................... 53
10.2.6.1 Collect ion Peri od.................................................................................... 53
10.2.6.2 Reporting AEs ........................................................................................ 53
10.2.6.3 Reporting SAEs ...................................................................................... 54
10.2.6.4 Reporting Special Interest AEs ............................................................... 54
10.2.6.5 Reporting of Abnormal Liver Function Tests .......................................... 54
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Mobocertinib
Study No. TAK -788-1008 Page 5of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIAL10.2.7 Safety Reporting to Invest igators, IRBs or IECs, and Regulatory  
Authori ties.................................................................................................. 55
10.2.8 Procedures for Reporting Product Complaints or Medicat ion Errors 
(Including Overdose) .................................................................................. 55
11.0 STATISTICAL METHODS .......................................................................................... 56
11.1 Statistical and Analyt ical Plans ................................................................................ 56
11.1.1 Analysis Sets ............................................................................................... 56
11.1.1.1 Pharmacokinet ic Set ............................................................................... 56
11.1.1.2 Safety Set............................................................................................... 56
11.1.1.3 Pharmacodynamic Set ............................................................................ 56
11.1.2 Analysis of Dem ography and Other Baseline Characterist ics....................... 56
11.1.3 Pharmacokinet ic Analysis ........................................................................... 56
11.1.4 Pharmacodynamic Analysis ........................................................................ 57
11.1.5 Safety Analysis ................................ ........................................................... 57
11.1.5.1 AEs ........................................................................................................ 57
11.1.5.2 Clinical Laboratory  Evaluat ion............................................................... 57
11.1.5.3 Vital Signs.............................................................................................. 57
11.1.5.4 Other Safet y Param eters ......................................................................... 57
11.2 Interim Analysis and Criteria for Early Terminat ion................................................ 57
11.3 Determinat ion of Sample Size .................................................................................. 58
12.0 QUALITY CONTROL AND QUALITY ASSURANCE ............................................... 59
12.1 Study -Site Moni toring Visit s................................................................................... 59
12.2 Protocol  Deviat ions.................................................................................................. 59
12.3 Qualit y Assurance Audits and Regulatory  Agency  Inspect ions................................ 59
13.0 ETHICAL ASPECTS OF T HE STUDY ........................................................................ 60
13.1 IRB and/or IEC Approval ........................................................................................ 60
13.2 Subject Informat ion, Inform ed Consent, and Subject Authorizat ion......................... 61
13.3 Subject Confidentialit y............................................................................................ 62
13.4 Publicat ion, Di sclosure, and Clinical Study  Registrati on Po licy............................... 62
13.4.1 Publicat ion and Disclosure .......................................................................... 62
13.4.2 Clinical Study  Registrati on.......................................................................... 63
13.4.3 Clinical Study  Resul ts Discl osure................................................................ 63
13.5 Insurance and Co mpensation for Injury .................................................................... 63
14.0 ADMINISTRATIVE AND R EFERENCE INFORMATION ......................................... 64
14.1 Administrative Informat ion...................................................................................... 64
14.1.1 Study  Contact Informat ion.......................................................................... 64
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Mobocertinib
Study No. TAK -788-1008 Page 6of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIAL14.1.2 Invest igator Agreement ............................................................................... 65
14.1.3 Study -Related Responsibilit ies.................................................................... 66
14.1.4 List of Abbreviat ions................................................................................... 66
15.0 DAT A HANDLING AND RE CORDKEEPING ............................................................ 68
15.1 CRFs (El ectronic and Paper) .................................................................................... 68
15.2 Record Retention ..................................................................................................... 68
16.0 REFERENCES .............................................................................................................. 70
17.0 APPENDICES ............................................................................................................... 71
LIST OF IN -TEXT TABLES
Table 1.a Study  Design ........................................................................................................ 8
Table 3.a Pharmacokinet ic Plasma Concentration Sampling Schedule ............................... 18
Table 4.a Derivat ion of Child -Pugh Classification Score 1................................................. 22
Table 4.b Determinat ion of Encephalopath y Grade 1.......................................................... 22
Table 6.a Study  Arms and Pl anned Dose ........................................................................... 26
Table 6.b Study  Design ...................................................................................................... 27
Table 7.a Excluded Medicat ions, Supplements, and Dietary  Products ................................ 37
Table 9.a Primary Specimen Collections ........................................................................... 45
Table 10.a Takeda Medically Significant AE List ................................................................ 51
LIST OF APPENDICES
Appendix A Responsibilit ies o f the Invest igator ..................................................................... 71
Appendix B Elements of the Subject Informed Consent ......................................................... 73
Appendix C Invest igator Consent to the Use of Personal Information .................................... 76
Appendix D Pregnancy and Contraception ............................................................................. 77
Appendix E Detailed Descript ion of Amendments to Text: Amendment 1 ............................. 79
Appendix F Detailed Descript ion of Amendments to Text: Amendment 2 ............................. 80
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Mobocertinib
Study No. TAK -788-1008 Page 7of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIAL1.0 STUDY SUMMARY
Name of Sponsor:
Millennium Pharmaceuticals, Inc. a wholly owned subsidiary of 
Takeda Pharmaceutical Company, Ltd
40 Landsdowne Street
Camb ridge, Massachusetts USA 02139
Telepho ne: +1 (617) 679-7000Compound:
Mobocertinib
Study Identifier: TAK -788-1008 (CA27459) Phase: 1
Protocol Title: Phase 1 Pharmacokinetics and Safety Study of Oral Mobocertinib in Subjects with Moderate or 
Severe Hepatic Impairment and Normal Hepatic Function
Trial Design:
This is an open -label, parallel -arm study of oral Mobocertinib designed to assess the PK of si ngle dose mobocertinib
and its active metabolites (AP32960 and AP32914) in subjects with moderate and/or severe hepatic impairment (HI) 
compared to matched -healthy  subjects with no rmal hepatic function. 
Approximately 8 subjects will be enrolled in each ar m of the study according to the following criteria:
Arm 1: Moderate HI (Child -Pugh B),
Arm 2: Severe HI (Child -Pugh C),
Arm 3: Normal hepatic function. Healthy subjects with normal hepatic function will be recruited to match both 
moderate and severe HI by age (mean ± 10 years), gender (± 2subjects per gender), and body mass index (BMI, 
mean ± 10%). 
The study will consist of a 21 -day screening period, a10 -day confinement period (Day −1 to Day 10) and a follow -up 
phone call 30 ±2 days after dosing.
For assessment of hepatic function, two hepatic function assessments are required prior to Day 1. These 2 assessments 
should be obtained during the screening period and on Day -1, at least 48 hours apart. If the Child -Pugh scores from 
these 2 assessments indicate the same liver function category for the subject (ie, normal function, moderate 
impairment, or severe impairment), mobo certinib can be administered as scheduled. If the results of the 2 assessments 
indicate different liver function categories, a third assessment must be conducted at least 24 hours after the second 
assessment. If the results of the 2 most recent assessments (the second and third) are in agreement with regard to the 
subject’s liver function category, the subject may be enrolled and should receive the Day 1 dose within 48 hours of the 
third assessment. If the second and third measurements differ, the subject w ill not be eligible for the study.
Subjects will be enrolled in a staggered manner. All moderate HI subjects may be enrolled concurrently however 
approximately 3 subjects in the moderate HI arm and approximately 3 subjects in the matched -normal hepatic fun ction 
arm must complete up to Day 10 study procedures prior to enrolling the subjects to the severe HI arm. An informal 
preliminary  PK data analysis of these subjects will be performed and may additionally leverage historical control PK 
data in healthy sub jects to gain an initial estimate of effect of moderate HI on the PK of mobocertinib and its active 
metabolites (AP32960 and AP32914). These preliminary data along with safety data will guide the decision to enroll 
the severe HI arm (for example, a decisio n will be made to dose the severe HI group at the same dose as the moderate 
HI arm, a reduced dose, or to not dose this arm). Following completion of enrollment of the moderate and severe HI (if 
enrolled) arms, the remaining subjects will be enrolled to th e matched -normal hepatic function arm. 
Subjects will receive a single oral dose of 40 mg mobocertinib on Day  1 (Table 1.a).
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Mobocertinib
Study No. TAK -788-1008 Page 8of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALTable 1.a Study Design
Study Day -1 1 2 3 4 5 6 8 10
Mobocertinib PO X
PK Blood Samples X X X X X X X X
Confinement in CRU X X X X X X X X X
CRU -clinical research unit; PK -pharmacokinetics; PO -per os (by mouth).
Blood samples will be collected from Days 1 to 10 at predetermined time points to characterize the PK and plasma 
protein binding of mobocertinib and its active metabolites (AP32960 and AP32914) in subjects with moderate and/or 
severe HI compared to matched -healthy  subjects with normal hepatic function.
Spirometry, as the pulmonary function test (PFT), may be performed in the event of a pulmonary adverse event (AE), 
if deemed clinically necessary by the Investigator or designee.
Subjects will be confined in the clinic research unit (CRU) until the morning of Day 10 after the 216 -hour PK sample 
collection for additional PK sample collections. A subject may be required to remain at the CRU for longer periods, at 
the discretion of the Investigator. Subjects may be admitted earlier than Day -1 for COVID -19 testing not related to 
study protocol as per CRU requirements .
A final safety follow up phone call will occur 30 ± 2 days after mobocertinib dosing to determine if any AEs have 
occurred since last study visit.
Study Primary Objective:
To characterize the single -dose plasma PK of mobocertinib and its active metabolites (AP32960 and AP32914) in 
subjects with moderate and/or severe HI compared to matched -healthy  subjects with normal hepatic function.
Study Secondar y Objectives:
1.To evaluate plasma protein binding of mobocertinib and its active metabolites (AP32960 and AP32914).
2.To assess the safety of mobocertinib following single oral dose in subjects with moderate and/or severe HI as well 
as matched- healthy  subject s with normal hepatic function.
Study Subject Population: Subjects will be enrolled in each arm of the study according to the following criteria:
Arm 1: Moderate HI (Child -Pugh B)
Arm 2: Severe HI (Child -Pugh C)
Arm 3: Normal hepatic function
Planned Num ber of Subjects:
At least 24 subjects will be enrolled into 3 arms (8 in 
each arm). 
Up to 16 healthy subjects may be enrolled into Arm 3 if 
it is not feasible to match the first 8 healthy subjects 
into both Arms 1 and 2. Planned Number of Sites:
At least 2
Dose Level:
40 mg Mobocertinib , single dose*
*The dose level for severe HI arm may be modified 
based on the preliminary results of approximately 
3moderate HI and 3 healthy matched subjects who 
completed up to Day 10 study procedures.Route of Administ ration:
Oral
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Mobocertinib
Study No. TAK -788-1008 Page 9of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALDuration of Treatment:
Day 1, subjects will receive a single oral dose of 
MobocertinibPlanned Study Duration :
Approximately 51 days ± 2 days including screening period 
and follow -up.
Main Criteria for Inclusion:
Healthy Subjects: 
The subject must fulfill the following inclusion criteria to be eligible for participation in the study:
1.Healthy , adult male or female subjects aged ≥18 to <80 years, at screening. Subjects will be matched to hepatic 
impaired subjects by age (mean ± 10 years) at screening.
2.Continuous non -smoker or moderate smoker ( ≤10 cigarettes/day or the equivalent) before screening. Subject 
must agree to consume no more than 5 cigarettes or equivalent/day from the 7 days prior to mobocertinib dosing 
and throughout the period of PK sample collection
3.Body mass index (BMI) ≥18.0 and ≤39.0 kg/m2, at screening. Subjects will be matched to hepatic impaired 
subjects by BMI (mean ± 10 %) at screening. At least 50% of the subjects will be required to be of BMI ≥18.0 and 
≤35.0 kg/m2, at screening.
4.Medically healthy with no clinically significant medical histor y, physical examination, laboratory profiles, vital 
signs or ECGs, as deemed by the Investigator or designee. Has liver function tests including alanine 
aminotransferase (ALT), asp artate aminotransferase (AST), alkaline phosphatase (ALP), and total bilirubin 
within the upper limit of normal at screening and at check -in.
5.Creatinine clearance (eGFR) ≥60 mL/min/1.73m2at screening.
6.Female subjects of nonchildbearing potential must have undergo ne one of the following sterilization procedures 
at least 6 months prior to dosing:
hysteroscopic sterilization;
bilateral tubal ligation or bilateral salpingectomy;
hysterectomy;
bilateral oophorectomy;
or be postmenopausal with amenorrhea for at least 1 year prior to dosing and follicle stimulating hormone (FSH) 
serum levels consistent with postmenopausal status.
7.Female subjects of childbearing potential will be advised to remain sexually inactive or to keep the same birth 
control method for at le ast 30 days following mobocertinib dosing as indicated in Appendix D.
8.Female subjects must agree not to donate ova/oocytes during the study and for at least 30 days following 
mobocertinib dosing as indicated in Appendix D.
9.Males subjects who are sexually active with a female partner of childbearing p otential must use barrier 
contraception as indicated in Appendix Dor abstain from sexual intercourse during the study until at least 30 days 
after mobocertinib dosing. Total abstinence (no sexual intercourse) may be considered an acceptable method of 
birth control if it agrees with his preferred and usual lifestyle.
10.Male subjects must agree not to donate sperm from dosing until at least 30 days after dosing as indicated in 
Appendix D.
11.Understands the study procedures in the ICF and be willing and able to comply with the protocol.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Mobocertinib
Study No. TAK -788-1008 Page 10of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALSubjects with Moderate or Severe Hepatic Impairment: 
The subject must fulfill the following inclusion criteria to be eligible for participation in the study: 
1.Adult male or female subjects aged ≥18 to <80 years, at screening.
2.Continuous non -smoker or moderate smoker ( ≤10 cigarettes/day or the equivalent) before screening. Subject 
must agree to consume no more than 5 cigarettes or equivalent/day from the 7 days prior to mobocertinib dosing 
and throughout the period of PK sample collection.
3.BMI ≥18.0 and ≤39.0 kg/m2, at screening. At least 50% of the subjects will be required to be of BMI ≥18.0 and 
≤35.0 kg/m2, at screening.
4.Aside from HI, be sufficiently healthy for study participati on based upon medical history, physical examination, 
vital signs, ECGs, and screening clinical laboratory profiles, as deemed by the Investigator or designee.
5.Creatinine clearance (eGFR) ≥60 mL/min/1.73m2 at screening.
6.Diagnosis of chronic (eg, imaging, biopsy, etc.) stable hepatic insufficiency for at least 6 months (no acute 
episodes of illness within the previous 2 months due to deterioration in hepatic function) with features of cirrhosis 
due to any  etiology according to medical history.
7.Chro nic HI fo r at least 3 months before screening, and the HI must be stable, ie, no significant changes in hepatic 
function in the 30 days preceding screening (or since the last visit if within 6 months before screening) and 
treatment with stable doses of medication. Has a score on the Child -Pugh Class ( Table 4.a) at screening as 
follows: 
Moderate HI arm, Child -Pugh Class B: ≥7 and ≤9
Severe HI arm, Child -Pugh Class C: ≥10 and ≤15
8.Female subjects of nonchildbearing potential must have undergone one of the following sterilization procedures 
at least 6 months prior to dosing:
hysteroscopic sterilization;
bilateral tubal ligation or bilateral salpingectomy;
hysterectomy;
bilateral oophorectomy;
or be postmenopausal with amenorrhea for at least 1 year prior to dosing and FSH serum levels consistent with 
postmenopausal status.
9.Female subjects of childbearing potential will be advised to remain sexually inactive or to keep t he same birth 
control method for at least 30 days following mobocertinib dosing as indicated in Appendix D.
10.Female subjects must agree not to donate o va/oocytes during the study and for at least 30 days following 
mobocertinib dosing as indicated in Appendix D.
11.Males subjects who are sexually active with a female partner of childbearing potential must use barrier 
contraception as indicated in Appendix Dor abstain from sexual intercourse during the study until at least 30 days 
after mobocertinib dosing. Total abstinence (no sexual intercourse) may be considered an acceptable method of 
birth control if it agrees with his preferred and usual lifestyle.
12.Male must agree not to donate sperm from dosing until at least 30 days after dosing as indicated in Appendix D.
13.Understands the study procedures in the ICF and be willing and able to comply with the protocol.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Mobocertinib
Study No. TAK -788-1008 Page 11of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALMain Criteria for Exclusion:
Healthy Subjects: 
The subject must be excluded from participating in the study if the subject: 
1.Mentally  or legally incapacitated or has significant emotional problems at the time of the screening visit or 
expected during the conduct of the study.
2.Histor y or presence of clinically significant medical or psychiatric condition or disease in the opinion of the 
Investigator or designee.
3.Histor y of any illness that, in the opinion o f the PI or designee, might confound the results of the study or poses an 
additional risk to the subject by their participation in the study.
4.Histor y or presence of alcoholism and drug abuse within the past 2 years prior to dosing.
5.Histor y or presence of c linically  significant hypersensitivity or idiosyncratic reaction to the study drug or related 
compounds.
6.Histor y or presence of any previous significant lung disease except childhood asthma.
7.Histor y of lung infection within 3 months of screening or ongoing lung infection.
8.Female subjects with a positive pregnancy test or who are lactating.
9.Positive results for urine or breath alcohol screen at screening or check -in.
10.Positive results for novel corona virus disease 2019 (COVID -19) testing at screening or check-in.
11.Positive results for urine or saliva drug screen at screening or check -in unless the positive drug screen is due to 
prescription drug use that is approved by the Investigator and Sponsor.
12.Positive result at screening for human immunodeficiency vi rus (HIV), hepatitis B surface antigen (HBsAg), or 
hepatitis C virus (HCV).
13.Seated blood pressure is less than 90/40 mmHg or greater than 150/95 mmHg at screening.
14.Seated heart rate is lower than 40 bpm or higher than 99 bpm at screening.
15.QTcF interval is ≥450 msec in males or ≥470 msec in females or has ECG findings deemed abnormal with clinical 
significance by the Investigator or designee at screening.
16.Unable to refrain from or anticipates the use of any medication or substance (including prescription or 
over-the-counter, vitamin supplements, natural or herbal supplements) as indicated in Section 7.3(Prohibitions 
and Concomitant Medication) for the prohibited time period.
17.Been on a diet incompatible with the on -study diet, in the opinion of the Investigator or designee, within the 30 
days prior to dosing and throughout the study.
18.Donation of blood or had significant blood loss within 56 days prior to dosing.
19.Plasma do nation within 7 days prior to dosing.
20.Participation in another clinical study within 30 days prior to dosing. The 30 -day window will be derived from the 
date of the last dosing in the pre vious study to Day 1 of the current study.
Subjects with Moderate or Severe Hepatic Impairment:
The subject must be excluded from participating in the study if the subject:
1.Mentally  or legally incapacitated or has significant emotional problems at the tim e of the screening visit or 
expected during the conduct of the study.
2.Histor y or presence of clinically significant medical, besides hepatic impairment, or psychiatric condition or 
disease in the opinion of the Investigator or designee.
3.Histor y of any  illness that, in the opinion of the Investigator or designee, might confound the results of the study 
or poses an additional risk to the subject by their participation in the study.
4.Histor y or presence of alcoholism and drug abuse within the past 6 months prior to dosing.
5.Histor y or presence of clinically significant hypersensitivity or idiosyncratic reaction to the study drug or related 
compounds.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Mobocertinib
Study No. TAK -788-1008 Page 12of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIAL6.Histor y or presence of any previous significant lung disease except childhood asthma.
7.Histor y of lung infectio n within 3 months of screening or ongoing lung infection.
8.Histor y of liver or other solid organ transplant.
9.Female subjects with a positive pregnancy test or who are lactating.
10.Positive results for urine or breath alcohol screen at screening or check -in.
11. P ositive results for COVID -19 testing at screening or check -in.
12.Positive results for urine or saliva drug screen at screening or check -in unless the positive drug screen is due to 
prescription drug use that is approved by the Investigator and Sponsor.
13.Posit ive result at screening for HIV. Hepatitis B surface antigen (HBsAg) positive subjects are allowed to enroll if 
HBV DNA is below 1000 copies/mL in the plasma. Subjects who are positive for anti -HCV antibody (HCVAb) 
can be enrolled but must not have detectable HCV RNA in the plasma. 
14.Seated blood pressure is less than 90/40 mmHg or greater than 150/95 mmHg at screening.
15.Seated heart rate is lower than 40 bpm or higher than 99 bpm at screening.
16.QTcF interval is >500 msec or has ECG findings deemed abnormal wi th clinical significance by the Investigator 
or designee at screening.
17.Unable to refrain from or anticipates the use of any medication or substance (including prescription or 
over-the-counter, vitamin supplements, natural or herbal supplements) as indicate d in Section 7.3(Prohibitions 
and Concomitant Medication) for the prohibited time period.
18.Been on a diet incompatible with the on -study diet, in the opinion of the Investigator or designee, within the 
30days prior to dosing and throughout the study.
19.Donation of blood or had significant blood loss within 56 days prior to dosing.
20.Plasma do nation within 7 days prior to dosing.
21.Participation in another clinical study within 30 days prior to dosing. The 30 -day window will be derived from the 
date of the last dosing in the previous study to Day 1 of the current study.
Study Endpoints:
Primary  Endpoints
The primary endpoints of the study are the following total and unbound PK parameters for TAK 788 and its active 
metabolites, AP32960 and AP32914 (total and unbound parameters in parenthesis, respectively):
Maximum observed concentration (C maxand C max,u).
Area under the concentration -time curve from time 0 t o infinity, calculated using the observed value of the last 
quantifiable concentration (AUC ∞and AUC ∞,u).
Area under the concentration -time curve from time 0 to the time of the last quantifiable concentration (AUC last
and AUC last,u). 
Time of first occurre nce of C max(tmax).
Terminal disposition phase half -life (t ½z).
Terminal disposition phase rate constant (λ z).
Apparent clearance after extravascular administration (CL/F and CL u/F) for mobocertinib only.
Apparent volume of distribution during the terminal disposition phase after extravascular administration (V z/F 
and V z,u/F) for mobocertinib only.
Secondary Endpoints
Pharmacokinetics:
Plasma protein binding of mobocertinib and its active metabolites (AP32960 and AP32914).
Safety:
Incidence of treatment emergent AEs (TEAEs) (including physical examination findings).
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Mobocertinib
Study No. TAK -788-1008 Page 13of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALClinical laboratory values.
12-lead ECG. 
Vital signs.
Statistical Considerations:
Pharmacokinetics:
The natural log (ln)-transformed of the combined molar unbound C max,u, AUC last,u, and AUC ∞,u, for mobocertinib and 
its metabolites (AP32960 and AP32914) will be compared between HI and the healthy arms using an analysis of 
variance (ANOVA) model. 
The ANOVA model will include HI versus normal conditions as a fixed effect and subject nested wit hin group as a 
random effect. Each ANOVA analysis will calculate the least -squares mean (LSM), the difference between group 
LSMs, and the standard error associated with the difference. Residual, subject nested within group, and intersubject 
variance will b e reported. Ratio of LSM and 90% confidence interval (CI) will be calculated using the exponential 
function of the difference between group LSMs from the analysis on the ln-transformed combined molar total and 
unbound C max,u, AUC last,u, and AUC ∞,u,for mobocertinib and its metabolite (AP32960 and AP32914). The same 
analy sis will be repeated for each analyte ( mobocertinib , AP32960, and AP32914) separately and will be performed 
on total PK parameters as well (C max, AUC last, and AUC ∞). 
Safety:
Safety data as well as the difference to baseline, when appropriate, will be summarized using the appropriate 
descriptive statistics.
Sample Size Justification:
The planned sample size of 8 subjects in each hepatic function arm represents a size that is considered adeq uate to 
provide a descriptive characterization of the PK of mobocertinib and its active metabolites (AP32960 and AP32914) 
in subjects with moderate or severe HI compared to healthy subjects with normal hepatic function.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Mobocertinib
Study No. TAK -788-1008 Page 14of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIAL2.0 STUDY SCHEMATIC
ScreeningTreatment
Follow -up aCheck -in and Predose 
AssessmentsMobocertinib Dosing, 
PK sampling, and 
Study Assessments PK sampling and Study Assessments
Within 21 days prior to dosing Day -1 Day 1 Day 2-10 a 30 days ± 2 following 
mobocertinib dose
Outpatient Visit Confinement b 
a The clinic will contact all subjects (including subjects who terminate the study early) 30 ±2days after the mobocertinib administration to determine if any adverse 
events have occurred since the last study visit.
bSubjects will start the confinement on Day -1 and be released from confinement after the 216 -hour study assessments (Day 10) are complete. At all times, subject s
may be required to remain at the clinical research unit for longer at the discretion of the Investigator or designee.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Mobocertinib
Study No. TAK -788-1008 Page 15of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIAL3.0 SCHEDULE OF STUDY PROCEDURES 
Study Procedures a
S bStudy Days
FU cDays in Period → -1 1 2 3 4 5 6 8 10
Hours → C-I d0 0.5 1 2 4 6 8 12 24 36 48 72 96 120 168 216
Administrative Procedures
Informed Consent X
Inclusion/Exclusion Criteria X X
Medical History X
Safety Evaluations 
Full Physical Examination eX X gX f
Height X
Weight X X g
Child -Pugh Assessment hX
12-Lead Safety ECG X X iX X X f
Vital Signs (HR and BP) X X iX X X X f
Vital Signs (RR and T) X
Pulmonary Function Test kX
Hem, Serum Chem j, Coag and UA X X X X f
Serum Pregnancy Test ( ♀only) X X
Serum FSH (PMP ♀only) X
Urine/saliva Drug Screen X X
Urine/breath Alcohol Screen X X
COVID -19 test X X
HIV/Hepatitis Screen X
AE MonitoringkX X
ConMeds Monitoring X
Study Drug Administration / PK
Mobocertinib Administration X
Blood for Mobocertinib and its X lX X X X X X X X X X X X X X X
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Mobocertinib
Study No. TAK -788-1008 Page 16of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALStudy Procedures a
S bStudy Days
FU cDays in Period → -1 1 2 3 4 5 6 8 10
Hours → C-I d0 0.5 1 2 4 6 8 12 24 36 48 72 96 120 168 216
Active Metabolite s(AP32960 and 
AP32914) PK
Blood for Protein Binding for 
Mobocertinib and its active 
metabolites (AP32960 and 
AP32914)X X X
Other Procedures
Confinement in the CRU mX
Visit X
a For details on Procedures, refer to Section 9.0.
b Within 21 days prior to study drug administration (Day 1). 
c The clinic will contact all subjects (including subjects who terminate the study early) 30 ± 2 days after study drug administration to determine if any AEs have occurred since the 
last study visit.
d Subjects will be admitted to the CRU on Day -1 at the time indicated by the CRU . Subjects may be admitted earlier than Day -1 for COVID -19 testing not related to study 
protocol as per CRU requirements.
e Full physical examination will be conducted as indicated. Symptom -driven physical examination may be performed, at the Investigator’s or designee’s discretion.
f To be performed at Day 10 or prior to early termination from the study.
g If the scr eening assessment was conducted within 4 -7 days prior to dosing (Day 1), assessment will be conducted at check- in only if, in the opinion of the Investigator, there is 
reason to believe they have substantially changed, otherwise the screening result will b e used. 
h For assessment of hepatic function, two hepatic function assessments are required prior to Day 1. These 2 assessments should be obtained during screening period and on Day -1, 
at least 48 hours apart. If the Child -Pugh scores from these 2 assessme nts indicate the same liver function category for the subject (ie, normal function, moderate impairment, or 
severe impairment), mobocertinib can be administered as scheduled. If the results of the 2 assessments indicate different liver function categories, a third assessment must be 
conducted at least 24 hours after the second assessment. If the results of the 2 most recent assessments (the second and thir d) are in agreement with regard to the subject’s liver 
function category, the subject may be enrolled a nd should receive the Day 1 dose within 48 hours of the third assessment. If the second and third measurements differ, the su bject 
will not be eligible for the study . Refer to Section 4.3.
i To be performed within 24 hours prior to dosing. 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Mobocertinib
Study No. TAK -788-1008 Page 17of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALj Samples for serum chemistry will be obtained following a fast of at least 8 hours, however, in case of dropouts or rechecks, subjects may not have fasted for 8 hours p rior to the 
serum chemistry sample is taken.
k Pulmonary function tests may be performed in the event of a pulmonary AE, if deemed clinically necessary by the Investigator or designee.
l To be performed prior to dosing.
m A subject may be required to remain at the CRU for longer periods, at the discretion of the Investigator.
Abbrevia tions: ♀ =Females, AE =Adverse events, BP =Blood pressure, C -I =Check -in, Chem =Chemistry, Coag = Coagulation, ConMeds =Concomitant medication, 
CRU =Clinical research unit, ECG =Electrocardiogram, FSH =Follicle -stimulating hormone, FU =Follow -up,Hem =Hematology, HIV =Human immunodeficiency virus, 
HR=Heart rate, PK =Pharmacokinetics, PMP =Postmenopausal, RR =Respiratory rate, S =Screening, T =Temperature, UA =Urinalysis. 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Mobocertinib
Study No. TAK -788-1008 Page 18of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALTable 3.a Pharmacokinetic Plasma Concentration Sampling Schedule
Study DaySample Collection 
TimeTime 
(Relative to Dosing)
h:minPlasma 
Concentrations of 
Mobocertinib , 
AP32960, and 
AP32914Plasma Protein 
Binding for 
Mobocertinib , 
AP32960, and 
AP32914
10 h
(predose)00:00
(predose)
0.5 h 00:30 (±5 min) 
1 h 01:00 (±10 min) 
2 h 02:00 (±10 min)  
4 h 04:00 (±10 min)  
6 h 06:00 (±20 min) 
8 h 08:00 (±20 min) 
12 h 12:00 (±20 min) 
2 0 h 24:00 (±30 min)  
12 h 36:00 (±30 min) 
3 0 h 48:00 (±30 min) 
4 0 h 72:00 (±60 min) 
5 0 h 96:00 (±60 min) 
6 0 h 120:00 (±60 min) 
8 0 h 168:00 (±60 min) 
10 0 h 216:00 (±60 min) 
Number of samples per subject: 16 3
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Mobocertinib
Study No. TAK -788-1008 Page 19of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIAL4.0 INTRODUCTION
4.1 Background
Aberrant activat ion of epidermal growth factor receptor (EGFR) and human epidermal growth 
factor 2 (HER2) plays a causal ro le in a subset of non –small cell lung cancer (NSCLC) and other 
cancers. As inhibit ion of wild -type (WT) EGFR i s associ ated wi th dose -limit ing toxicit ies, a 
tyrosine kinase inhibitor (TKI) that inhibits oncogenic EGFR and HER2 variants more potently  
than WT EGFR is more likely to be dosed at the more efficacious levels. Mult iple classes of 
activat ing mutations have been i dentified in EGF R and HER2 that vary  widely in their sensit ivity 
to available TKIs. Mobocertinib , formerly known as AP32788 and TAK -788, was designed to be a 
potent, select ive inhibitor of all act ivated forms of EGFR and HER2, including exon 20 insertions 
(not targeted by any approved TKI), more potently than it inhibits WT EGFR.
Non-Clinical Pharmacokinetics
Following oral  administrati on in rats and dogs, urinary  and biliary  excret ions of unchanged drug 
were negligible (<0.3% and 0.54% -7.9% respectively). In Sprague -Daw ley rats, mobocertinib
was eliminated almost completely  (97.46% ± 1.70% of the radioactive dose) through feces, and 
urinary  excreti on was insignificant (1.98% ± 0.16%). Most of the dose (88.54%) was excreted in 0 
to 24 hours. In bile duct -cannulated rats, the average total recovery  of administered radioactivit y 
(0-
72hours) was 103.38% ±4.03%, with most of the eliminat ion through bile (57.76% ± 4.19%), 
indicat ing that metabo lism was the major clearance mechanism.
In vitro studies indicated that the metabo lism o f mobocertinib was primarily mediated by  
CYP3A4/5, with minor contribut ions from CYP2C8, 2C9, 2C19, and 2D6.
Clinical Pharmacokinetics
The clinical development program for mobocertinib includes an ongoing phase 1/2 clinical 
efficacy  and safety  study  in pat ients with NSCLC (AP32788 -15-101) and 2 completed clinical 
pharmaco logy studi es: 1) Single ri sing dose study  (Part 1), low -fat meal effect study  (Part 2), and 
relative bioavailabilit y study  (Part 3) in healt hy subjects (TAK -
788-1001); and 2) a drug -drug 
interact ion (DDI) study  to characteri ze mobocertinib DDI wi th either a strong cy tochrome P -
450 
(CYP)3A inhibitor, itraconazole (Part 1) or with a strong CYP3A inducer, rifampin (Part 2) in 
healt hy subjects (TAK -788- 1006); and 2 ongoing clinical pharmaco logy studi es: TAK - 788-1002, 
and -1004. The object
ives and study design of these studies are presented in mobocertinib IB 
Edition 4 (IB 2020). Only preliminary PK results from AP32788 -15-101, and final PK results fro m 
TAK -
788-1001 and TAK - 788-1006 are presented in this document.
In the AP32788 -15-101 study , following oral  administrati on of  mobocertinib once daily (QD), 
mobocertinib was readily absorbed with a median time to reach C maxconcentrati on (T max) of 4 
hours postdose. The single -dose C maxand area under the plasma concentration -time curve fro m 
time 0 to 24 hours postdose (AUC 24) following m ultiple doses increased i n a less than dose 
proporti onal manner across the dose range of 5 to 180 mg.
Minimal to modest mobocertinib accum ulation ratios were observed at steady  state (geom etric 
mean range 1.23 to 1.52) in the dose range of 20 to 120 mg QD. At 160 mg QD, the geomet ric 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Mobocertinib
Study No. TAK -788-1008 Page 20of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALmean accumulat ion rati o following repeated doses was 1.06, suggesting autoinduct ion of the 
apparent oral clearance o f mobocertinib likely via induct ion of CYP3A.
The em erging finding of autoinduction by  mobocerti nibat the 160 mg QD dose is consistent with 
the resul ts of in vitro induct ion studi es that have shown concentration -dependent CYP3A 
induct ion by mobocertinib and i ts active m etabo lites, suggest ing a possible risk for drug -drug 
interact ions due to induct ion of CYP3A and other co -regul ated enzyme s/transporters by  
mobocertinib as a potenti al perpetrator. The PK of the 2 active metabolites (AP32960 and 
AP32914) of mobocertinib were al so evaluated in clinical studies. Systemic exposures to 
metabo lites AP32960 and AP32914 in terms of molarAUC 24were a pproximately 
62% (%CV: 25%) and 8% (%CV: 13%) of parent AUC 24respectively. 
In the healt hy subject study  TAK -788-1001, a l ow-fat meal (i e, ≤350 calori es and ≤15% calories 
from fat) did not affect the PK o f mobocertinib in healthy subjects. At 160 mg mobocertinib, 90% 
CIs of the GMR with a low- fat m eal versus fasted condit ions for C max(GMR 0.964) and AUC ∞
(GMR 0.951) fell co mpletely wit hin 80 -125% range.
In the TAK -788- 1006 study , a DDI between the CYP3A4 inhibitor, itraconazole, and 
mobocertinib was obse rved. Following coadministration of mult iple oral doses of 200 mg 
itraconazo le wit h a single oral dose of 20 mg mobocertinib , overall (AUC ∞) and peak (C max) 
exposures were increased by approximately  743% and 282% from  the corresponding values 
obtained fo llowing mobocertinib alone. Similar resul ts were observed for combined mo lar AUC ∞
and co mbined mo lar C maxdata when comparing itraconazole + mobocertinib to mobocertinib
alone. A significant reduction in mobocertinib AUC ∞and C maxwas observed when mobocerti nib
was concomitant ly administered with the strong CYP3A4 inducer, rifampin. Fo llowing 
coadministration of mult iple oral doses of 600 mg rifampin wit h a single oral dose of 160 mg 
mobocertinib , overall (AUC ∞) and peak (C max) exposures were reduced by appro ximately 96% and 
95%, respectively, compared to the corresponding values obtained fo llowing mobocerti nibalone. 
Similar results were observed for combined mo lar AUC ∞and co mbined mo lar C maxdata when 
comparing rifampin + mobocertinib to mobocertinib alone.
Refer to the Invest igator’s Brochure (IB) for detailed background informat ion and safet y data on 
mobocertinib IB Edi tion 4
(IB 04 -Jan-2020).
4.2 Rationale for the Proposed Study
Mobocertinib , formerly known as AP32788 and TAK -788, was designed to be a selective inhibitor 
of all m utant f orms of EGFR and HER2, including exon 20 insert ions (not i ndicated by  any 
approved TKI), and has shown clinically more potent inhibit ion of these mutant variants than WT 
EGFR. Mobocertinib is neither a m utagenic nor genotoxic agent and was generally well tolerated 
in the previous clinical pharmaco logy studi es (TAK -
788-1001 and TAK - 788-1002, a total of 
65subjects) in healt hy subjects in the single dose range o f 20 
–160 mg.
After entering the body , drugs are eliminated by  excreti on and/or metabolism. Alt hough 
eliminat ion can occur through a variet y of routes, most drugs are cleared by metabolism in the liver 
and/or sm all intestine and/or by  eliminat ion of unchanged drug by  the ki dney. Liver di sease is
associ ated wi th several  pathophysi ologic changes that may  alter the PK of a drug. These include 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Mobocertinib
Study No. TAK -788-1008 Page 21of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALalterati ons in hepat ic blood flow, changes in liver enzyme act ivity, decreased binding of drug to 
plasma proteins, and impaired biliary  excret ion (Rodi ghiero, 1999 andVerbeeck, 2008 ) .
Accordingly , current Uni ted States (US) FDA guidance recommends a PK study  in pat ients with 
impaired hepatic funct ion if hepat ic metabo lism and/or excretion accounts for a substant ial portion 
(≥20 percent of the absorbed drug) of the eliminat ion of a parent drug or active metabo lite (FDA 
2003). 
Metabo lism via mult iple cy tochrom e P450s (CYPs) appears to be the major route of eliminat ion 
for mobocerti niband urinary  excretion of  the parent drug i s low (<5% of dose as unchanged 
mobocertinib excreted in urine in healt hy subjects). In vitro human liver microsomal metabo lism 
studi es have shown that mobocerti nibundergoes oxidat ive biotransformat ion by hepat ic 
cytochrom e P450 enzymes primarily CYP3A4/5, forming 2 act ive metabolites (AP32960 and 
AP32914). Sin ce mobocertinib and i ts 2 active metabolites inhibit EGFR exon 20 insertions with 
similar potency  and com parable plasma unbound fractions in vitro, the effect of HI on the 
combined mo lar exposure to mobocertinib and i ts 2 active m etabo lites, adj usted for m olecular 
weight, will  be characteri zed in this study  to establish scient ifically guided dosing 
recommendat ions in these special pat ient populat ions.
The result of preliminary PK analysis based on the data from clinical study  (AP32788-15- 101) in 
patients wi th NSCLC shows that the combined molar C avof mobocertinib and i ts 2 active 
metabo lites (dose -normalized on C1D1) is not impacted by  mild HI, supporting a commo n dose 
between these patients with mild HI and pat ients wit h norm al hepati c function. Because th e 
inclusio n criteria of hepatic function based on total bilirubin laboratory  values at the baseline in 
clinical study AP32788 -15-101 (<1.5x upper limit of normal [ULN]) result in inclusio n of patients 
with mild HI (based on NCI ODWG criteria) who would be expected to fall into the same 
categori zation of mild HI determined by  Child -Pugh score, ( Mansfield, 2016 ) subjects with mild 
HI are not included in this HI study  (TAK -788-1008), given the clinical safet y and PK data 
available from these cancer pati ents in the mobocerti nibclinical program . However, no 
inform ation is available on the PK of mobocertinib and its 2 active metabo lites in pat ients with 
moderate or severe HI. Therefore, this study  will evaluate the PK of mobocertinib and i ts active 
metabo lites fo llowing oral administration in subjects with moderate or severe HI using Child -Pugh 
scores, 
(FDA 2003 ) com pared to m atched -healthy subjects wi th normal  hepatic function.
4.3 Child -Pugh Clas sification of Hepatic Impairment
The Child -Pugh classificat ion (Table 4.a) will be used to categorize HI due to its widespread use 
and acceptance by reg ulatory  agencies (including the US FDA [FDA 2003 ]and the European 
Medicines Agency [ EMA 2005 ]. This study  design is supported by  FDA gui delines for drugs that 
undergo substant ial hepat ic metabo lism and for which a dosage guideline is sought for subjects 
with HI.
In the current study, subjects with chronic, stable HI with features of cirrhosis due to any etio logy 
will be enro lled, and the Child -Pugh scale will be used to classify the severi ty of liver disease. The 
scale emplo ys 5 clinical measures o f liver disease listed in Table 4.a. Each m easure is scored 1 to 
3, wi th 3 indicat ing most severe derangemen t. The bilirubin score in the table is dependent upon 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Mobocertinib
Study No. TAK -788-1008 Page 22of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALthe type of cirrhosis (primary biliary cirrhosis versus all other causes). Subjects’ scores of 5 to 6, 7 
to 9, and 10 to 15 on this scale are classified as having mild (Child -Pugh A), moderate (Child -Pugh
B), and severe (Child -Pugh C)hepat ic failure, respectively.
Table 4.a Derivation of Child -Pugh Classification Score 1
Parameter 1 Point 2 Points 3 Points
Serum albumin (g/dL) >3.5 2.8 to 3.5 <2.8
Total serum bilirubin (mg/dL) <2.0 2.0 to 3.0 >3.0
Prothrombin time (sec prolonged) 
or international normalized ratio (ratio) <4
<1.704 to 6
1.70 to 2.30>6
>2.30
Ascites Absent Slight Moderate or Subject on 
medication(s) to control 
ascites
Hepatic encephalopathy (see Table 4.b) None Grade 1 or 2 Grade 3 or 4 or subject 
receiving medication(s) 
to prevent 
encephalopathy
Table 4.b Determination of Encephalopathy Grade 1
Encephalopathy Grade Definition
0 Normal consciousness, personality, neurological exam
1 Restless, sleep disturbed, irritable/agitated, tremor, impaired handwriting
2 Lethargic, time-disoriented, inappropriate, asterixis, ataxia
3aSomnolent, stuporous, place -disoriented, hyperactive reflexes, rigidity
4aUnrousable coma, no personality/behavior, decerebrate
a Subjects with clinically active Grade 3 or 4 encephalopathy are excluded.
1Adapted from FDA Guidance for Industry. Pharmacokinetics in Patients with Impaired Hepatic Function: Study 
Design, Data Analysis, and Impact on Dosing and Labeling (FDA 2003 ).
Two hepatic funct ion asses sments are required prior to Day  1. These 2 assessments should be 
obtained during the screening period and on Day  -1, at l east 48 hours apart. If the Child -Pugh 
scores fro m these 2 assessments indicate the same liver funct ion category  for the subject 
(ie,norm al functi on, m oderate impai rment, or severe impairment), mobocertinib can be 
administered as scheduled. If the results of the 2 assessments indicate different liver function 
categori es, a thi rd assessment m ust be conducted at least 24 hours after the s econd assessment. If 
the results of the 2 most recent assessments (the second and third) are in agreement with regard to 
the subject’s liver function category , the subject may  be enrolled and should receive the Day  1 
dose wi thin 48 hours of the third asses sment. If the second and third measurements differ, the 
subject will not be eligible for the study .
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Mobocertinib
Study No. TAK -788-1008 Page 23of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIAL4.4 Benefit/Risk Profile
The clinical safet y data available as of 27 January 2020 indicated no particular safety findings that 
are unique to m obocertinib compar ed wi th other approved EGFR TKIs. The most commo n 
treatm ent-emergent AEs (TEAE) occurring in ≥20% of patients by preferred term overall were 
diarrhea (84.7%), nausea (45.3%), decreased appetite (31.0%), vomit ing (31.0%), fatigue (30.0%), 
and anemia (23.2%) . There i s some variet y in the characterizat ion of TEAEs of the skin result ing 
in different PTs to describe it. The most common skin -related PTs were rash (30.5%), dry  skin 
(23.6%), maculo -papul ar rash (17.2%), paronychia (14.8%), derm atitis acneiform (12. 3%), and 
pruri tus (10.8%) (IB2020 ).
There will be no direct healt h benefit for study participants from receipt of study drug. An indirect 
healt h benefit to the subjects enrolled in this study  is the free medical tests received a t screening 
and during the study .
The risk of dosing mobocertinib in subjects with hepatic impairment ( HI)is unknown in this study. 
The ri sk of dosing mobocertinib in subjects wi th RI is unknown. However, the risk of a single 40 
mg dose of mobocertinib administered in this study is ant icipated to be similar to those previously 
reported studies in the mobocertinib IB (IB 20 20).
The inclusio n and exclusio n criteria, screening, and safet y monitoring practices emplo yed by  this 
protocol  (ie, 12 -lead ECG, vital signs, clinical laboratory tests, AE questioning, and physical 
examinat ion are adequate to protect the subject’s safet y and should detect all TEAEs.
Mobocertinib
Study No. TAK -788-1008 Page 24of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIAL5.0 STUDY OBJECTIVES AND ENDPO INTS
5.1 Hypothesis
Not applicable
5.2 Study Objectives
5.2.1 Study Primary Objective
To characterize the single -dose pl asma PK of mobocertinib and i ts active metabolites (AP32960 
and AP32914) in subjects with moderate and/or severe HI compared to matched -healt hy subjects 
with norm al hepat ic function.
5.2.2 Study Secondary Objectives
The secondary  objectives of the study  are:
1.To evaluate plasma protein binding of mobocertinib and i ts active metabolites (AP32960 and 
AP32914).
2.To assess the safet y of mobocertinib following singl e oral  dose in subjects wi th moderate 
and/or severe HI as well as matched -healthy subjects wi th norm al hepat ic function.
5.2.3 Study Exploratory Objective
 
5.3 Endpoints
5.3.1 Primary Endpoint
The primary  endpoints of the study  are the fo llowing total  and unbound PK parameters for 
mobocertinib and its active metabo lites, AP32960 and AP32914 (total and unbound parameters in 
parenthesis, respectively):
Maximum observed concentration (C maxand C max,u).
Area under the concentration -time curve fro m time 0 to infinit y, calculated using the observed 
value of the last quantifiable concentration ( AUC and AUC ,u).
Area under the concentration -time curve from t ime 0 to the time of the last quantifiable 
concentration (AUC lastand AUC last,u). 
Time o f first occurrence of C max(tmax). 
Terminal disposit ion phase half -life (t ½z).
Terminal disposit ion phase rate constant (λ z).

Mobocertinib
Study No. TAK -788-1008 Page 25of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALApparent cl earance after extravascular administra tion (CL/F and CL u/F) for mobocertinib
only.
Apparent volume o f distribut ion during the terminal disposit ion phase after extravascular 
administration (V z/F and V z,u/F) for mobocertinib only.
5.3.2 Secondary Endpoints 
Pharmacokinet ics:
Plasma protein binding of mobocertinib and i ts active metabolites (AP32960 and AP32914).
Safety:
Incidence of TEAEs assessments (including physical examinat ion findings).
Clinical laboratory  testing.
12-lead ECG.
Vital signs.
5.3.3 Exploratory Endpoint 
 

Mobocertinib
Study No. TAK -788-1008 Page 26of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIAL6.0 STUDY DESIGN AND DESCRIPTI ON
6.1 Study Design 
This is an open -label, parallel -arm study  of oral mobocertinib designed to assess the PK of single 
dose mobocertinib and i ts active metabolites (AP32960 and AP32914) in subjects with moderate 
and/or severe HI compared to matched -healt hy subjects wi th norm al hepat ic function. 
The pl anned doses of mobocertinib per study  arm are outlined in  Table 6.a. 
Table 6.a Study Arms and Planned Dose
Study Arms
ArmNumber of 
Subjects ClassificationChild -Pugh 
Category (a) Dose ( b)
1 8 Moderate B 40 mg
2 8 Severe C 40 mg (may be 
reduced) (d)
3 8-16 (d) Matched -Healthy  (c) 40 mg
(a) Refer to Section 4.3for the classification system.
(b) Single orally administered dose at Hour 0 on Day 1. Subjects will be enrolled in a staggered manner beginning with 
approximately 3 subjects in moderate impairment arm followed by approximately 3 subjects in matched -normal 
hepatic function arm.
(c) Healthy subjects with normal hepatic function will be recruited to match both moderate and severe HI arms by age 
(mean ± 10 years), gender (± 2 subjects per gen der), and body mass index (BMI, mean ± 10%).
(d) If the dose of Arm 2 is reduced then an additional 8 healthy matched subjects will be dosed in Arm 3 at the 
corresponding dose level to the Arm 2.
The study  will consist of a 21 -day screening perio d, a 10-day confinement period (Day  −1 to 
Day 10) and a fo llow-up phone call 30 ± 2 days after dosing.
For assessment of hepat ic function, two hepatic funct ion assessments are required prior to Day 1. 
These 2 assessments should be obtained during screening peri od and on Day -1, at l east 48 hours 
apart. If the Child -Pugh scores fro m these 2 assessments indicate the same liver funct ion category 
for the subject (ie, normal funct ion, moderate impairment, or severe impairment), mobocertinib
can be administered as sch eduled. If the results of the 2 assessments indicate different liver 
funct ion categories, a third assessment must be conducted at least 24 hours after the second 
assessment. If the results of the 2 most recent assessments (the second and third) are in agre ement 
with regard to the subject’s liver funct ion category, the subject may be enrolled and should receive 
the Day  1 dose wi thin 48 hours of the third assessment. If the second and third measurements 
differ, the subject will not be eligible for the study .
Subjects will be enro lled in a staggered manner. All moderate HI subjects may be enro lled 
concurrent ly however approximately 3 subjects in the moderate HI arm and approximately 
3subjects in the matched -norm al hepatic funct ion arm  must com plete up to Day  10 study  
procedures prior to enrolling the subjects to the severe HI arm. An informal preliminary PK data 
analysis of these subjects will be performed and may  addi tionally leverage historical control PK 
Mobocertinib
Study No. TAK -788-1008 Page 27of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALdata in healthy subjects to gain an init ial est imate o f effect of m oderate HI on the PK of 
mobocertinib and i ts active m etabo lites (AP32960 and AP32914). These preliminary data along 
with safet y dat a will guide the decision to enroll the severe HI arm (for example, a decisio n will be 
made to dose the severe HI group at the same dose as the moderate HI arm, a reduced dose, or to 
not dose this arm). Following co mpletion of enro llment of the moderate and severe HI (if enrolled) 
arms, the remaining subjects will be enrolled to the matched -norm al hepat ic function arm. 
Subjects will receive a single oral dose of 40 mg mobocertinib on Day  1 ( Table 6.b).
Table 6.b S tudy Design 
Study Day Screening -1 1 2 3 4 5 6 8 10
Mobocertinib PO X
PK Blood Samples X X X X X X X X
Confinement in CRU X X X X X X X X X
CRU -clinical research unit; PK -pharmacokinetics; PO -per os (by mouth).
Blood samples will be co llected fro m Days 1 to 10 at predetermined t ime points to characterize the 
PK and plasma protein binding of mobocertinib and i ts active m etabo lites (AP32960 and 
AP32914) in subjects with moderate and/or severe HI compared to matched -healthy subjects with 
norm al hepatic funct ion.
Subjects will be confined in the CRU unt il the morning of Day 10 after the 216 -hour PK sample. A
subject may be required to remain at the CRU for longer periods, at the discret ion of the 
Invest igator. Subjects may be admitted earlier than Day  -1 for COVID -19 testing not related to 
study  protocol  as per CRU requirements .
A final safet y follow up phone call will occur 30 ± 2 days after mobocertinib dosing to determine if 
any AEs have occurred since last study  visit.
6.2 Dose Escalation
An informal preliminary  PK data analysis will be performed on approximately  3 moderate HI 
subjects and 3 healt hy matched subjects who completed study  procedures up to Day 10 and m ay 
additionally  leverage histori cal control  PK data in healt hy subjects to gain an init ial estimate of 
effect of moderate HI on the PK of mobocerti niband i ts active m etabolites (AP32960 and 
AP32914). These preliminary  data al ong wi th safety  data will gui de the deci sion to enroll  the 
severe HI arm (for example, a decisio n will be made to dose the severe HI group at the same dose 
as the m oderate HI arm, a reduced dose, or t o not dose this arm). 

Mobocertinib
Study No. TAK -788-1008 Page 28of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIAL6.3 Rationale for Study Design, Dose, and Endpoints
6.3.1 Rationale of Study Design 
This study  design is supported by  the Food and Drug Administration (FDA) guidelines for drugs 
which undergo substant ial hepatic m etabo lism and for which an in dicat ion is sought for subjects 
with hepat ic insufficiency (FDA 2003 ). The FDA gui dance reco mmends that a cohort of subjects 
with normal hepat ic funct ion representative of the typical pat ient populat ion be used as a reference 
arm in HI PK studies. Demographically matched adult healthy subjects will be used as the 
reference arm to detect clinically relevant PK differences. These subjects will be matched to 
subjects wi th impaired hepat ic funct ion by age, BMI, and gende r.
6.3.2 Rationale for Dose 
The dose selected for this study  with moderate and/or severe HI is 40 mg of mobocertinib taken 
orally; this corresponds to 25% of the highest single oral dose evaluated in healt hy subjects 
(ie,160 mg) and will  provide a safety  margin. In the event that HI reduces drug clearance and 
increases overall systemic exposure, it is ant icipated that a single oral dose 40 mg administered to 
patients wi th severe HI will not exceed the historical exposure levels seen in healt hy subjects of a 
single oral  dose of 160 m g dose of mobocertinib. 
Following review of the preliminary  PK and safety data of approximately 3 moderate HI subjects 
and 3 healt hy matched subjects who completed up to Day 10 study  procedures, a decisio n to dose 
the severe HI at th e sam e dose as the moderate HI arm will be made to ensure a similar safet y 
margin in the severe HI group; alternat ively a reduced dose may also be proposed or the severe HI 
group m ay not be dosed.
6.3.3 Rationale for Endpoints
6.3.3.1 Pharmacokinetic Endpoints
Given tha t mobocertinib , AP32960, and AP32914 are pharmacologically  active, with similar 
in-vitro potency to inhibit EGFR/HER2 exon 20 insertions, the statistical analyses of PK exposure 
param eters will  be perform ed on the m olecularly wei ght adj usted combined expos ure of 
mobocertinib and i ts 2 active metabolites alo ng with the exposure parameters of mobocertinib , 
AP32960, and AP32914 individually .
It is well known that hepat ic dysfunct ion will impact expressio n and activit y of drug metabo lizing 
enzymes by which unbo und drugs, if they are substrates of these enzymes, are mediated. As 
mobocertinib and i ts 2 active metabolites display  high binding to pl asma proteins in vitro, plasma 
protein binding of mobocertinib and i ts 2 active metabolites may vary wit h hepat ic dysfu nction in 
humans. Therefore, the statistical analyses of PK exposure parameters will be conducted using the 
unbound PK values.
Mobocertinib
Study No. TAK -788-1008 Page 29of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIAL6.3.3.2 Safety Endpoints 
The key safet y endpo ints are typical  for Phase 1 studies and will be assessed through monitoring o f 
adverse eve nts, vital signs, ECGs, laboratory  assessments and physical examinat ions.
6.3.4 Future Biomedical Research
Any residual plasma samples will be stored by  the Sponsor or Bi oanaly tical facilit y for the 
maximal 5 years determined by Sponsor following dosing and may be used in the future to perform 
metabo lite profiling. Tubes or container will be ident ified wit h a barcode using an appropriate 
label.
No di seases/condit ions, deoxy ribonucleic acid, or ribo nucleic acid will be the focus of these 
analyses. The analyses will focus on m etabo lite profiling for mobocertinib compound. Samples 
will not be submitted to a public database. The Sponsor and contract research organizat ions 
involved in the clinical conduct, bioanalyt ical analyses and PK and statist ical analysis o f the data 
will have access to the samples and/or the data that resulted from the analysis, if performed. 
By signing the ICF, subjects agree to the possible future analysis of these samples. At any time, the 
subjects can contact the CRU staff to request destruct ion of the residual samples once PK 
assessments required to meet the primary object ive of the study  are com pleted. Any  addi tional 
research on these samples unspecified by this protocol will require approval from the subjects.
6.3.5 Critical Procedures Based on S tudy Objectives: Timing of Procedures 
For thi s study , the cri tical com ponent is the blood collect ion for plasma concentrati ons of 
mobocertinib and i ts active m etabo lites (AP32960 and AP32914) and samples are required to be 
collected, as appropriate, as cl ose to the scheduled times defined in this protocol as possible.
6.4 Study Design/Dosing/Procedures Modifications Permitted Within Protocol 
Parameters
Severe HI arm only: The dose of mobocerti nibmay be reduced following review of preliminary  
PK and safet y data of approximately 3 HI subjects and 3 healt hy subjects. If reduced, the dose for 
the matched -healt hy subjects will be modified as well.
The dose and administration of mobocertinib for subjects in the moderate HI arm and their 
matched -healt hy subjects may not be m odified.
If necessary, a subject may be discontinued for the reasons described in Section 7.6and 
Secti on7.7.
6.5 Study Beginning and End/Completion
6.5.1 Definition of Beginning of the Study
The beginning of the study  will be defined as the beginning of the screening (ie, signing of the 
ICF) of the first subject.
Mobocertinib
Study No. TAK -788-1008 Page 30of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIAL6.5.2 Definition of End of the Study
The end o f study  is defined as the date of the last scheduled study  procedure at the clinic as 
outlined in the Schedule o f Study  Procedures (Sectio n  3.0).
6.5.3 Definition of Study Completion
The end o f the study  is scheduled after complet ion of the evaluat ions in the fo llow-up phone call 
for the l ast subject in the study .
This time period may change in the event that the study is terminated early or the last subject is lost 
to fo llow-up.
6.5.4 Definition of Study Discontinuation
Celeri on and/or the clinical site reserves the right to terminate the study  in the interest of subject 
welfare.
The Sponsor reserves the right to suspend or terminate the study  at any  time.
6.5.5 Criteria for Premature Termination or Suspension of the Study
The study  will be com pleted as pl anned unless one or more of the fo llowing cri teria are satisfied 
that require temporary  suspensi on or early  terminati on of  the study :
New info rmation or other evaluat ion regarding the safet y or efficacy  of the study  medicat ion 
that indicates a change in the known risk/benefit profile for the product, such that the risk is no 
longer acceptable for subjects participat ing in the study .
Significant violation of Good Clinical Practice (GCP) that compromises the ability to achieve 
the primary  study  objectives or compromises subject safet y.
6.5.6 Criteria for Premature Termination or Suspension of a Site
There i s no predetermined criteria for terminat ion of s uspensi on of a site. 
Terminat ion or suspensio n of a site may occur at any t ime at the discretion of the Sponsor. 
Mobocertinib
Study No. TAK -788-1008 Page 31of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIAL7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS
7.1 Inclusion Criteria
7.1.1 Inclusion Criteria for Healthy Subjects
All healthy subjects m ust fulfill the fo llowing inclusion criteria to be eligible for participat ion in 
the study : 
1.Healthy, adul t male or female subjects aged ≥18 to <80 years, at screening. Subjects will be 
matched to hepatic impaired subjects by age (mean ± 10 y ears) at screening.
2. C ontinuous non -smoker or m oderate sm oker (≤10 cigarettes/day or the equivalent) before 
screening. Subject must agree to consume no more than 5 cigarettes or equivalent/day fro m the 
7 day s prior to mobocertinib dosing and throughout the period of PK sample c ollection
3.BMI ≥18.0 and ≤39.0 kg/m2, at screening. Subjects will be matched to hepatic impaired 
subjects by BMI (mean ± 10 %) at screening. At least 50% of the subjects will be required to be 
of BMI ≥18.0 and ≤35.0 kg/m2, at screening.
4.Medically  healthy wi th no clinically  significant m edical history , physical examinat ion, 
laboratory  profiles, vi tal signs or ECGs, as deemed by  the Invest igator or designee. Has liver 
funct ion tests including ALT, AST, ALP, and total bilirubin wit hin the upper limit of normal at 
screening and at check -in.
5.Creatinine clearance (eGFR) ≥60 m L/min/1.73m2at screening.
6.Female subjects of nonchildbearing potential must have undergone one of the fo llowing 
sterilizat ion procedures at least 6 months prior to dosing:
hysteroscopic sterilization;
bilateral  tubal  ligation or bilateral  salpingectomy;
hysterectomy;
bilateral  oophorectomy;
or be postmenopausal wit h amenorrhea for at least 1 year prior to dosing and FSH serum levels 
consistent with postmenopausal status.
7.Female subjects of childbearing potential will be advised to remain sexually inact ive or to keep 
the sam e birth control  method for at l east 30 days following mobocertinib dosing as indicated 
in Appendix D.
8.Female subjects must agree not to donate ova/oocytes during the study and for at least 30 days 
following mobocertinib dosing as indicated in Appendix D.
9.Males subjects who are sexually active with a female partner of childbearing potential must 
use barrier contraception as indicated in Appendix Dor abstain fro m sexual intercourse during 
the study  until at least 30 day s after mobocertinib dosing. Total abst inence (no sexual 
Mobocertinib
Study No. TAK -788-1008 Page 32of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALintercourse) m ay be considered an acceptable method of birth control if i t agrees wi th his 
preferred and usual lifest yle.
10.Male subjects must agree not to donate sperm fro m dosing unt il at least 30 days after dosing as 
indicated in Appendix D.
11.Understands the study  procedures i n the ICF and be willing and able to comply  with the 
protocol .
7.1.2 Inclusion Criteria for Subjects with Moderate or Severe Hepatic Impairment
All HI subjects must fulfill the fo llowing inclusio n criteria tobe eligible for participation in the 
study : 
1.Adult male or female subjects aged ≥18 to <80 y ears, at screening.
2.Continuous non -smoker or m oderate sm oker (≤10 cigarettes/day or the equivalent) before 
screening. Subject must agree to consume no more than 5 cigarettes or equivalent/day fro m the 
7 day s prior to mobocertinib dosing and throughout the period of PK sample collect ion.
3.BMI ≥18.0 and ≤39.0 kg/m2, at screening. At least 50% of the subjects will be required to be of 
BMI ≥18.0 and ≤35.0 kg/m2, at screening.
4.Aside from HI, be sufficient ly healthy for study  parti cipati on based upon m edical history , 
physical examinat ion, vital signs, ECGs, and screening clinical laboratory profiles, as deemed 
by the Invest igator or designee.
5.Creatinine clearance (eGFR ) ≥60 m L/min/1.73m2at screening.
6.Diagnosis of chronic (eg, imaging, biopsy, etc.) stable hepat ic insufficiency for at least 
6months (no acute episodes of illness within the previous 2 months due to deterioration in 
hepat ic function) wi th features of ci rrhosis due to any  etiology according to m edical history .
7.Chronic HI for at least 3 months before screening, and the HI must be stable, ie, no significant 
changes in hepat ic function in the 30 days preceding screening (or since the last visit if within 
6 months before screening) and treatment with stable doses of medication. Has a score on the 
Child -Pugh Cl ass (Table 4.a) at screening as fo llows: 
Moderate HI arm, Child -Pugh Cl ass B: ≥7 and ≤9.
Severe HI arm, Child -Pugh Class C: ≥10 and ≤15.
8.Female subjects of nonchildbearing potential must have undergone one of the fo llowing 
sterilizat ion procedures at least 6 months prior to dosing:
hysteroscopic steriliza tion;
bilateral  tubal  ligation or bilateral  salpingectomy;
hysterectomy;
bilateral  oophorectomy;
Mobocertinib
Study No. TAK -788-1008 Page 33of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALor be postmenopausal wit h amenorrhea for at least 1 year prior to dosing and FSH serum levels 
consistent with postmenopausal status.
9.Female subjects of childbearing potential will be advised to remain sexually inact ive or to keep 
the sam e birth control  method for at l east 30 days following mobocertinib dosing as indicated 
in Appendix D.
10.Female subjects must agree not to donate ova/oocytes during the study and for at least 30 days 
following mobocertinib dosing as indicated in Appendix D.
11.Males subjects who are sexually active with a female partner of childbearing potential must 
use barrier contraception as indicated in Appendix Dor abstain fro m sexual intercourse during 
the study  until at least 30 day s after mobocertinib dosing. Total abst inence (no sexual 
intercourse) m ay be considered an acceptable method of birth control if it agrees with his 
preferred and usual lifest yle.
12.Male m ust agree not to donate sperm fro m dosing unt il at least 30 days after dosing as 
indicated in Appendix D.
13.Understands the study  procedures i n the ICF and be willing and able to comply  with the 
protocol .
7.2 Exclusion Criteria
7.2.1 Exclusion Criteria f or Healthy Subjects
All healthy subjects m ust be excluded from  parti cipating in the study  if the subject: 
1.Mentally or legally incapacitated or has significant emotional problems at the time o f the 
screening visit or expected during the conduct of the stud y.
2.History  or presence of clinically significant medical or psy chiatri c condi tion or di sease in the 
opinio n of the Invest igator or designee.
3.History  of any illness that, i n the opinio n of the PI or designee, might confound the results of 
the study  or poses an addit ional risk to the subject by their participat ion in the study .
4.History  or presence of alcoho lism and drug abuse within the past 2 years prior to dosing.
5.History  or presence of clinically significant hy persensi tivity or i diosyncrat ic reaction to th e 
study  drug or rel ated com pounds.
6.History  or presence of any previous significant lung disease except childhood asthma.
7.History  of lung infect ion within 3 m onths of screening or ongoing lung infect ion.
8.Female subjects with a positive pregnancy test or who are lactating.
9.Positive results for urine or breath alcoho l screen at screening or check- in.
10.Positive results for COVID -19 testing at screening or check -in.
Mobocertinib
Study No. TAK -788-1008 Page 34of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIAL11.Positive results for urine or saliva drug screen at screening or check -in unless the posit ive drug
screen is due to prescript ion drug use that is approved by  the Invest igator and Sponsor.
12.Positive result at screening for HIV, HBsAg, or HCV.
13.Seated bl ood pressure is less than 90/40 mmHg or greater than 150/95 mmHg at screening.
14.Seated heart rate is lowe r than 40 bpm or higher than 99 bpm at screening.
15.QTcF interval is ≥450 m sec in males or ≥470 msec in females or has ECG findings deemed 
abnorm al with clinical  significance by the Investigator or designee at screening.
16.Unable to refrain fro m or anti cipates the use of any medicat ion or substance (including 
prescri ption or over -the-counter, vitamin supplements, natural or herbal supplements) as 
indicated in Section 7.3(Prohibit ions and Conco mitant Medi cation) for the prohibited time 
period.
17.Been on a diet inco mpat ible with the on -study  diet, in the opinio n of the Investigator or 
designee, within the 30 days pri or to dosing and throughout the study .
18.Donati on of  blood or had si gnificant bl ood l oss wi thin 56 days pri or to dosing.
19.Plasma donat ion within 7 days pri or to dosing.
20.Parti cipation in another clinical study  within 30 days prior to dosing. The 30 -day window will 
be derived from the date of the la st dosing in the previous study  to Day 1 of the current study .
7.2.2 Exclusion Criteria for Subjects with Moderate or Severe Hepatic Impairment s
All HI subjects must be excluded fro m participat ing in the study  if the subject: 
1.Mentally or legally incapacitated or has significant emotional problems at the time o f the 
screening visit or expected during the conduct of the study .
2.History  or presence of clinically significant medical, besides hepat ic impairment, or 
psychiatric condit ion or disease in the opinio n of t he Investigator or designee.
3.History  of any illness that, i n the opinio n of the Investigator or designee, might confound the 
resul ts of the study  or poses an addit ional risk to the subject by their participat ion in the study.
4.History  or presence of alcoho lism and drug abuse within the past 6 months prior to dosing.
5.History  or presence of clinically significant hy persensi tivity or i diosyncrat ic reaction to the 
study  drug or rel ated com pounds.
6.History  or presence of any previous significant lung disease excep t childhood asthma.
7.History  of lung infect ion within 3 m onths of screening or ongoing lung infect ion.
8.History  of liver or other solid organ transplant.
9.Female subjects with a positive pregnancy test or who are lactating.
10.Positive results for urine or breat h alcoho l screen at screening or check- in.
Mobocertinib
Study No. TAK -788-1008 Page 35of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIAL11.Positive results for COVID -19 testing at screening or check -in.
12.Positive results for urine or saliva drug screen at screening or check -in unless the posit ive drug 
screen is due to prescript ion drug use that is approved by  the Invest igator and Sponsor.
13.Positive result at screening for HIV. HBsAg posit ive subjects are allowed to enroll if HBV 
DNA is below 1000 copies/mL in the plasma. Subjects who are positive for HCVAb can be 
enrolled but must not have detectable HC V RNA in the pl asma. 
14.Seated bl ood pressure is less than 90/40 mmHg or greater than 150/95 mmHg at screening.
15.Seated heart rate is lower than 40 bpm or higher than 99 bpm at screening.
16.QTcF interval is >500 msec or has ECG findings deemed abnormal wit h clinical  significance 
by the Invest igator or designee at screening.
17.Unable to refrain fro m or anti cipates the use of any medicat ion or substance (including 
prescri ption or over -the-counter, vitamin supplements, natural or herbal supplements) as 
indicated in S ection  7.3(Prohibit ions and Conco mitant Medi cation) for the prohibited time 
period.
18.Been on a diet inco mpat ible with the on -study  diet, in the opini on of the Investi gator or 
designee, within the 30 days pri or to dosing and throughout the study .
19.Donati on of  blood or had si gnificant bl ood l oss wi thin 56 days pri or to dosing.
20.Plasma donat ion within 7 days pri or to dosing.
21.Parti cipation in another clinica l study  within 30 days prior to dosing. The 30 -day window will 
be derived from the date of the last dosing in the previous study  to Day 1 of the current study .
7.3 Prior and Concomitant Medications and Therapies
Concomitant therapies include any  therapies, over -the-counter medicat ions, herbal products, 
vitamin and/or mineral supplements used by a subject from Day  1 through the l ast PK sam ple on 
Day 10. A record of all medicat ions used will be maintained for each s ubject throughout the study. 
Reported informat ion will include a descript ion of the ty pe of  drug, treatm ent peri od, dosing 
regimen, the route of administration, and drug indication. 
Subjects will be instructed to inform the study  Investi gator of  the detai ls (indicat ion, dose and 
dates of administration) if they take any medication prior to clinic check -in, and these details will 
be recorded in the CRF. 
Healthy subjects will be restricted of using any  prescri ption medicat ions/products and any  
over-the-coun ter, non -prescri ption preparations (including herbal products, natural or herbal 
supplements) from at least 14 days before dosing and throughout the study. However, healt hy 
subjects that are on stable medicat ion for at least 30 day s prior to dosing may  be enrolled upon 
approval  by the Invest igator (or designee) and Sponsor.
Subjects with HI who are taking medicat ions to treat manifestations of hepat ic disease or 
medicat ions needed to treat for stable diseases (eg, diuret ics, angiotensin converting enzyme 
Mobocertinib
Study No. TAK -788-1008 Page 36of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALinhibitors, angi otensin II receptor antagonists, beta -blockers, lactulose, rifaximin or antibiot ics 
used for spontaneous bacterial peritonit is like fluoroquino lones) will be allo wed to participate in 
the study  at the discret ion of the Invest igator and follow ing consultat ion with the Sponsor. 
Subjects m ust be on a stable dose (steady dose, drug, and regimen) for at least 14 days able to 
withhol d the use for at least 4 hours post -dose. Phosphate binders containing aluminum, calcium, 
or lanthanum salt s; iron supplements or other m etal cations; H2- receptor antagonists (except 
cimet idine); or mult ivitamins containing iron or zinc must be withheld at least 8 hours before 
dosing and at least 6 hours postdose.
If a subject with HI is prescribed prohibited medication, upon discussio n between the Sponsor and 
the Invest igator, the Invest igator may substitute the previously prescribed medicat ion to an 
allowed one for the purpose of this study .
For all subjects, any drugs known to be strong or moderate inhibitors of CYP3A e nzymes and/or 
P-gp will be restricted for 14 day s, and any drugs known to be strong or moderate inducers of 
CYP3A enzymes and/or P -gp, including St. John’s Wort, will be restricted for 28 days, before 
dosing and throughout the study . Use of weak inhibitors or inducers m ay be deemed acceptable 
following consultation wit h the Sponsor and the Investigator or designee. Appropriate sources (eg, 
Flockhart Tabl eTM) will  be consul ted to confirm  lack of  PK/pharmacodynamic interaction with 
study  drug.
For all subjects, fo llowing dosing, acetaminophen (up to 2 g per 24 hours) may be administered at 
the discret ion of the Invest igator or designee. Thyroid hormone replacement medication may be 
permitted if the subject has been on the same stable dose for the immedi ate 3 m onths pri or to 
dosing.
All medications taken by subjects during the course of the study  will be recorded.
Concurrent medicat ion during the course of the study  including both prescri ption and 
non-prescripti on drugs may  be permitted based on the timin g of study  drug administrati on and i ts 
pharmaco logy, but m ust fi rst be di scussed with the Invest igator or designee and Sponsor prior to 
dosing, unless appropriate medical care necessitates that therapy  shoul d begin before the 
Invest igator or designee and S ponsor can be consulted. 
7.4 Excluded Medications ,Supplements, Dietary Products
Use of excluded agents (prescript ion or non -prescript ion) or dietary  products i s outlined in 
Table 7.a.
Mobocertinib
Study No. TAK -788-1008 Page 37of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALTable 7.a Excluded Medications, Supplements, and Dietary Products
CategoryBetween Screening and Dosing (Days -28 to 
predose [Day 1])After Dosing (Day 1) through 
Follow -up 
Alcohol Prohibited from 48 hours prio r to dosing Prohibited up to Day 10, 
inclusively
Xanthine and/or Caffeine Prohibited from 24 hours prio r to dosing aProhibited up to Day 10, 
inclusivelya
Medications See Sections 7.2and 7.3 See Sections 7.1and 7.3
Food substance
Grapefruit/Seville orange Prohibited from 28 days prior to dosing Prohibited up to Day 10, 
inclusively
asmall amounts of caffeine derived from normal foodstuffs eg, 250 mL/8 oz./1 cup decaffeinated coffee or other 
decaffeinated beverage, per day, with the exception of espresso; 45 g/1.5 oz. chocolate bar, per day, would not be 
considered a deviation to this restriction. 
If deviat ions occur, the Investigator will decide on a case -by-case basis whether the subject may 
continue participation in the study  based on the time the drugs were administered and their 
pharmaco logy.
7.5 Diet, Fl uid, Activity 
7.5.1 Diet and Fluid
Water (except water provided wit h oral  dosing) will be restricted 1 hour prior to and 1 hour after 
study  drug administrati on, but will be allowed ad libitum at all other times. Other fluids may be 
given as part of meals and sn acks but will  be restricted at all other times throughout the 
confinement period.
On Day  1, subjects will  fast overnight for at least 10 hours prior to oral study  drug administration 
and will cont inue to fast for at least 4 hours postdose. When confined, s tandard m eals and snacks 
will be provided at appropriate times, except when they are required to fast. When confined in the 
CRU, subjects will be required to fast fro m all food and drink except water between meals and 
snacks. Each meal and/or snacks served at the CRU will be standardized and will be similar in 
caloric content and composit ion.
7.5.2 Activity
Subjects will remain ambulatory  or seated upri ght for the first 4 hours postdose on Day 1, except 
when they  are supine or semi -reclined for study  procedures o r AEs.
Subjects will be instructed to refrain fro m strenuous physical act ivity which coul d cause m uscle 
aches or i njury , including contact sports at any  time fro m screening unt il completion of the study .
Depending on the CRU rules and regulat ions, subjects may be prohibited fro m smoking during 
their confinement or during portions o f their confinement. 
Mobocertinib
Study No. TAK -788-1008 Page 38of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIAL7.6 Criteria for Discontinuation or Withdrawal of a Subject
Subjects are free to withdraw from the study  at any time for any  reason. 
In addit ion, subjects may  be wit hdrawn from the study  by the Invest igator or designee for the 
following reasons:
AEs.
A posi tive pregnancy  test f or females.
Positive drug or alcoho l resul ts.
Difficult ies in blood collect ion.
A subject may be wit hdrawn by the Investigator (or design ee) or the Sponsor if enrollment into the 
study  is inappropri ate, the study  plan i s violated, or for administrative and/or other safet y reasons
7.7 Procedures for Discontinuation or Withdrawal of a Subject
The Invest igator may discont inue a subject’s study par ticipat ion at any t ime during the study when 
the subject meets the study termination criteria described in Section  7.3. In addition, a subject may 
discontinue his or her participat ion without giving a reason at any  time during the study . Shoul d a 
subject’s participat ion be di scontinued, the primary  criterion for terminat ion must be recorded by  
the Invest igator. In addition, efforts should be made to perform all proced ures scheduled for the 
end-of-study  or early terminat ion as described in Section  3.0.
7.8 Subject Replacement
Replacement of discont inued or withdrawn subjects due to any reason will be assessed on a case 
by case basis by the Sponsor and Invest igator to ensure approximately 8 PK -evaluable subjects 
complete in each arm  of the study . In the event of a dose change for the severe HI arm, addit ional 
healt hy-matched subjects may be enrolled at the discretion of the Sponsor up to 8 subjects.
Mobocertinib
Study No. TAK -788-1008 Page 39of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIAL8.0 CLINICAL STUDY MATER IAL MANAGEMENT
8.1 Clinical Study Drug 
A single 40 mg dose of mobocertinib (1 x 40 m g mobocertinib capsule) will be administered on 
Day 1.
Mobocertinib drug product i s a nonsterile, oral, capsule dosage form. Mobocertinib succinate salt 
is the act ive pharmaceutical ingredient encapsul ated in a hard gelat in capsule shell wit h no 
excipients.
Mobocertinib (AP32788) 40 mg: Si ze 1, whi te, opaque, hard gel atin capsules, 30 capsules per 
bottle.
Mobocertinib (AP32788) 20 mg: Size 2, Swedish -orange, opaque, gelat in capsules, 30 capsules 
per bot tle.
The 20 m g capsules o f mobocertinib has been provided to allow dose modificat ion for the severe 
HI group if the moderate HI group interim data indicates the 40 mg dose is not well tolerated.
8.1.1 Clinical Study Drug Labeling
Mobocertinib capsule containers will be affixed with a clinical label in accordance wit h local 
regul atory  requi rements.
The pharmacy at the CRU will provide the dose in individual unit dose containers for each subject.
8.1.2 Clinical Study Drug Inventory and Storage
The Sponsor will supply suf ficient quantit ies of mobocertinib products to allow complet ion of this 
study . 
Store below 30°C (86°F).
Do not refrigerate or freeze –Norm al room  temperature.
Keep away fro m cold or heat sources.
Keep out of reach and sight of children.
Records will be made of the recei pt, preparation, dispensing, and final disposit ion of the study  
drugs supplied.
8.1.3 Clinical Study Drug Blinding
This is an open -label study .
8.1.4 Randomization Code Creation and Storage 
Not applicable.
Mobocertinib
Study No. TAK -788-1008 Page 40of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIAL8.1.5 Clinical Study Blind Maintenance/Unblinding Procedure
Not applicable.
8.1.6 Accountability and Destruction of Sponsor- Supplied Drugs
At the conclusio n of the study , any unused mobocerti nibstudy  drug will  be retained by the CRU, 
returned to the Sponsor or designee, or destroy ed, as per Sponsor instruction s. If no supplies 
remain, this fact will be documented in the pharmacy  product accountabilit y records.
Mobocertinib
Study No. TAK -788-1008 Page 41of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIAL9.0 STUDY PROCEDURES
The fo llowing sect ions describe the study procedures and data to be collected. For each procedure, 
subjects are to be assessed by the sa me Investigator or site personnel whenever possible. The 
Schedule of Study  Procedures i s located in Sect ion  3.0.
9.1 Administrative Procedures
9.1.1 Informed Consent Procedu re
The requi rements of the informed consent are described in Sect ion  13.2.
Inform ed consent m ust be obtained prior to the subject entering into the study , and before any 
protocol -directed procedures are performed, including requesting that a subject fast for laboratory 
evaluat ions.
9.1.1.1 Assignment of Screening and Allocation Numbers 
Each subject will be assigned a unique ident ificat ion number upon screening. Subjects who 
complete the study  screening assessments and meet all the eligibilit y criteria will be assigned a 
unique identificat ion number at the time of dosing, different from the screening number.
If replacement subjects are used, the replacement subject number will be 100 m ore than the 
original  (eg, Subject No. 101 will replace Subject No. 1).
9.1.1.2 Study Drug Assignment
All subjects will receive mobocertinib as detailed in Section 8.1.
9.1.2 Inclusion and Exclusion 
Subjects must satisfy all o f the inclusio n criteria and meet none of the exclusio n criteria as outlined 
in Sections 7.1and 7.2, respectively in their applicable study  arm.
9.1.3 Medical History/ Demography
Medical history  and dem ographic data, including subject number, sex, age, race, ethnicit y, and 
history  oftobacco use will be recorded.
9.1.4 Concomitant Medications
Concomitant medicat ions will be prohibited as listed in Sections  7.2and 7.3. All medicat ions 
taken by  subjects during the course of the study  will be recorded.
9.2 Clinical Procedures and Assessments
The Schedule o f Study  Procedures (Secti on3.0) summarizes the clinical procedures to be 
perform ed at each visit. Indivi dual clinical  procedures are described in detail below. Addit ional 
evaluat ions/testing may be deemed necessary  by the Invest igator or designee and/or the Sponsor 
for reasons rel ated to subject safet y.
Mobocertinib
Study No. TAK -788-1008 Page 42of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALFor this study, the collect ion of blood for mobocertini band its metabo lites is the crit ical parameter 
and needs to be collected as close to the exact time point as possible. All other procedures should 
be co mpleted as close to the prescribed/scheduled time as possible, but can be performed prior to 
or after the prescribed/scheduled time (refer to Table 3.a).
Any nonscheduled procedures required for urgent evaluat ion of safet y concerns take precedence 
over all routine scheduled procedures.
9.2.1 Full Physical Examination
A full physical examinat ion will be performed as outlined in the Schedule o f Study  Procedures 
(Secti on3.0). Symptom -driven physical examinat ions may be performed at other times, if deemed 
necessary  by the Invest igator or designee.
9.2.2 Height and Weight
Body  height (cm) and weight (kg) will be reported as outlined in the Schedule of Study Procedure s 
(Secti on3.0).
9.2.3 Body Mass Index
Subject BMI will be calculated based on the height and weight measured at screening.
9.2.4 Vital Signs
Single measurements of body  temperature, respi ratory  rate, bl ood pressure, and heart rate, will be 
measured as outlined in the Schedule of Study  Procedures (Secti on3.0). Addit ional vital signs 
may be taken at any  other times, if deemed necessary .
Blood pressure and heart rate measurements will be performed with subjects in a seated posit ion, 
(subjects must be seated for at least 5 minutes prior to measurem ent), except when they are supine 
or semi -reclined because of study  procedures and/or AEs (eg, nausea, dizziness) or if deemed 
necessary  by the Invest igator or designee.
Blood pressure and heart rate will be measured within 24 hours prior to Day 1 dosing f or the 
predose time po int. When scheduled postdose, vital signs will be performed wit hin approximately 
15minutes of the scheduled time po int.
9.2.5 12-Lead ECG
Single 12 -lead ECGs will be performed as outlined in the Schedule of Study Procedures 
(Secti on3.0). Addit ional ECGs may  be taken at any  other times, if deemed necessary  by the 
Invest igator or designee.
ECGs will be performed with subjects in a sup ine posit ion. Subjects are required to be supine for at 
least 5 minutes prior to the ECG measurement. All ECG tracings will be reviewed by the 
Invest igator or designee.
Mobocertinib
Study No. TAK -788-1008 Page 43of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALECGs will be measured within 24 hours prior to Day 1 dosing for the predose time point. When 
scheduled postdose, ECGs will be performed wit hin approximately 20 minutes of the scheduled 
time point.
9.2.6 Pulmonary Function Test
9.2.6.1 Spirometry
Spirometry as the PFT m ay be perf ormed in the event of a pulmo nary AE, if deemed clinically 
necessary  by the In vestigator or designee.
9.2.7 Study Drug Administration
Mobocertinib oral capsules will be provided as described in Sect ion  8.1.
Subjects will be instructed not to crush, split, or chew the m obocertinib capsules.
Mobocertinib will be administered fo llowing an overnight fast.
Mobocertinib will be administered with approx imately 240 mL o f water. The exact clock time of 
oral dosing will be recorded.
The pharmacy at the CRU will provide study  drug in individual unit dose containers for each 
subject as appropriate.
9.2.8 AE Monitoring
Subjects will be mo nitored throughout the study  for adverse reactions to the study  drug and/or 
procedures as described in Section 10.0.
9.2.9 Laboratory Pr ocedures and Assessments
All tests listed below will be performed as outlined in the Schedule of Study  Procedures 
(Secti on3.0). In addit ion, laboratory  safet y tests may be performed at various unscheduled time 
points, if deemed necessary  by the Invest igator or designee.
Mobocertinib
Study No. TAK -788-1008 Page 44of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIAL9.2.9.1 Clinical Laboratory Tests
Hematology
Hem atology will consist of the following tests:
Hemoglobin Red blood cell count
Hematocrit Platelet count
Total and differential leukocyte count
Coagulation
Coagulation will consist of the fo llowing tests:
Prothrombin time International normalized ratio
Chemistry 
Serum  chemistry  tests will be performed after at least an 8 -hour fast; however, in case o f dropouts 
or rechecks, subjects may not have fasted for 8 hours prior to when the serum chemistry sample is 
taken.
Chemistry  evaluat ions will consist of the fo llowing standard chemistry  panel:
Amylase Albumin
Lipase Sodium
Blood Urea Nitrogen Potassium
Bilirubin (total and direct) Chloride
Alkaline phosphatase Glucose 
Aspartate aminotransferase Creatinine *
Alanine aminotransferase (ALT) Magnesium
* At screening, creatinine clearance will be calculated using the Cockcroft -Gault formula.
Urinalysis
Urinalysis will consist of the fo llowing tests:
pH Bilirubin
Specific gravity Blood *
Protein * Nitrite *
Glucose Urobilinogen
Ketones Leukocyte esterase *
* If urinalysis is positive for protein, blood, nitrite and/or leukocyte esterase, a microscopic examination (for red blood 
cells, white blood cells, bacteria, casts, and epithelial cells) will be performed.
Mobocertinib
Study No. TAK -788-1008 Page 45of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALOther 
HIV test Urine or saliva drug screen
–Opiates (includes morphine, heroin 
(diacetylmorphine), codeine, 6 -acetylmorphine, 
dihydrocodeine, hy drocodone, thebaine, and, 
hydromorphone)
–Amphetamines
–Barbiturates
–Benzodiazepines
–Cocaine
–CannabinoidsHBsAg ( if HI patients are positive for HBV, DNA 
copies are below 1000 copies/mL in plasma)
HCV (if antibody positive, confirm RNA negative)
Urine or breath alcohol screen
Serum pregnancy test (for females only)
FSH (for postmenopausal females only)
COVID -19 testing (performed according to CRU 
standard procedures , provided in a separate 
document[s])
9.3 Pharmacokinetic Samples
Instructi ons for plasma samples processing and handling will be provided in a separate document. 
Primary specimen co llection parameters are provided in Table 9.a.
Table 9.a Primary Specimen Collections
Specimen NamePrimary 
Specimen Description of Intended UseSample 
Collection
Plasma sample for Mobocertinib and 
metabolites PK TotalPlasma Plasma sample for Mobocertinib and 
metabolites PK analysisMandatory
Plasma sample for Mobocertinib and 
metabolites protein bindingPlasma Plasma sample for Mobocertinib and 
metabolites protein bindingMandatory
9.3.1 PK Measurements 
9.3.1.1 Plasma PK Measurements
Total  and unbound plasma PK parameters for mobocertinib and metaboli tes (AP32960 and 
AP32914) will be calculated as fo llows, as appropriate, following oral administration:
AUC last: The area under the concentration versus time curve, from time 0 to the last 
observed non- zero concentration, as calculated by  the linear trapezoidal 
method for total analy te.

Mobocertinib
Study No. TAK -788-1008 Page 46of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALAUC last,u: The area under the concentration versus time curve, from time 0 to the last 
observed non- zero concentration, as calculated by  the linear trapezoidal 
method for unbound analyte.
AUC : The area under the concentration versus time curve, from time 0 
extrapol ated to infinit y. AUC is calculated as AUC last plus the rati o of the 
last measurable blood concentration to the eliminatio n rate constant for total 
analyte.
AUC ∞,u: The area under the concentration versus time curve, from time 0 
extrapol ated to infinit y. AUC ∞,uis calculated as AUC last,u plus the ratio of the 
last m easurable blood concentration to the eliminatio n rate constant for 
unbound analy te.
AUC %extrap : Percent of AUC ∞extrapol ated, represented as (1 -AUC last/AUC ∞)*100.
CL/F Apparent total plasma clearance after oral (extravascular) administration, 
calculated as Dose/AUC (mobocertinib only).
CL u/F Apparent total plasma clearance after oral (extravascular) administration, 
calculated as Dose/AUC ,u(mobocertinib only).
Cmax: Maximum observed concentration for total analyte.
Cmax,u: Maximum observed concentration for unbound analyte.
tmax: Time to reach C max. If the maximum value occurs at more than one time 
point, t maxis defined as the first time po int with this value.
t½z: Apparent first -order terminal eliminat ion half-life will be calculated as 
0.693/λ z.
Where λ zis the apparent first order terminal elimination rate constant 
calculated from  a semil og pl ot of  the pl asma concentrati on versus time 
curve. The parameter will be calculated by  linear least -squares -regression 
analysis using the maximum number of points i n the terminal log- linear 
phase (eg, three or more non -zero plasma concentrations).
Vz/F Apparent volume o f distribut ion during the terminal eliminat ion phase after 
oral (extravascular) administration, calculated as Dose/(AUC x λ z) 
(mobocertinib only).
Vz,u/F Apparent volume o f distribut ion during the terminal eliminat ion phase after 
oral (extravascular) administration, calculated as Dose/(AUC ,ux λ z) 
(mobocertinib only).
No val ue for λ z, AUC , AUC ,u, AUC %extrap , CL/F, CL u/F, V z/F, V z,u/F, or t ½zwill be reported for 
cases that do not exhibit a terminal log -linear phase in the concentration versus time profile. 
No PK parameters will be calculated for subjects with detectable concentrations at 2 or fewer 
consecut ive time po ints. 
Mobocertinib
Study No. TAK -788-1008 Page 47of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALIndividual and me an pl asma concentrati on-curves (both linear and log -linear) will be included in 
the final report.
9.3.2
 
 
 
9.3.3 PGx Measurements 
Not applicable
9.3.4 Confinement
Subjects will be housed on Day  -1, at the time indicated by the CRU, until the morning of Day 10 
after the 216 -hour PK sample is co llected and study procedures are complete, as indicated in the 
Secti on 3.0.  At all t imes, a subject may be required to remain at the CRU for longer at the 
discreti on of  the Investi gator or desi gnee.

Mobocertinib
Study No. TAK -788-1008 Page 48of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIAL10.0 ADVERSE EVENTS
10.1 Definitions and Elements of AEs
An AE is defined as any untoward medical o ccurrence in a clinical invest igation subject who has 
signed inform ed consent to participate in a study; it does not necessarily  have to have a causal 
relationship with the treatment.
An AE can therefore be any unfavorable and unintended sign (eg, a clinic ally significant abnormal 
laboratory  finding), symptom, or disease temporally  associ ated wi th the use of a drug, whether or 
not it is considered related to the drug.
An untoward finding generally may:
Indicate a new diagnosis or unexpected worsening of a p reexist ing condit ion. (Intermittent 
events for pre -exist ing condit ions or underlying disease should not be considered AEs.)
Necessitate therapeutic intervent ion.
Requi re an invasive diagnostic procedure.
Requi re discontinuation or a change in dose of study medicat ion or a concomitant medicat ion.
Be considered unfavorable by the Investigator for any reason.
Diagnoses versus signs and symptoms:
Each event should be recorded to represent a single  diagnosis. Acco mpanying signs (including 
abnorm al laboratory  values or ECG findings) or symptoms should NOT be recorded as 
additional AEs. If  a diagnosis is unknown, sign(s) or symptom(s) should be recorded 
appropriately  as an AE(s).
Laboratory  values and ECG findings:
Changes in laboratory  values or ECG param eters may be considered AEs if they are judged to 
be clinically  significant (i e, if som e act ion or intervent ion is required or if the Invest igator 
judges the change to be beyo nd the range of normal physio logic fluctuati on). A l aboratory  
re-test and/or continued moni toring of an abnormal value are not considered an intervention. In 
addition, repeated or addit ional noninvasive testing for verificat ion, evaluat ion or m onitoring 
of an abnorm ality is not considered an intervention.
If abnormal laboratory values or ECG findings are the result of pathology for which there is an 
overall diagnosis (eg, increased creat inine in renal failure), the diagnosis only should be 
reported appropriately  as an AE.
Pre-exist ing condit ions:
A pre -exist ing condit ion (present at the time of signing of informed consent) is considered a 
concurrent medical history  condi tion and shoul d NOT be recorded as an AE. A baseline 
evaluat ion (eg, laboratory  test, ECG, X -ray, etc) shoul d NOT be recorded as a n AE unless 
related to a study  procedure. However, if the subject experiences a worsening or complicat ion 
Mobocertinib
Study No. TAK -788-1008 Page 49of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALof such a concurrent medical history  condi tion, the worsening or complication should be 
recorded appropriately as an AE (worsening or complicat ion occ urs after informed consent is 
signed). Invest igators should ensure that the event term recorded captures the change in the 
condi tion (eg, “worsening of…”).
If a subject has a pre -exist ing episodic condit ion (eg, asthma, epilepsy), any occurrence of an 
episode shoul d only  be captured as an AE if the episodes become more frequent, serious, or 
severe in nature, that is, Investigators should ensure that the AE term recorded captures the 
change from Baseline in the condit ion (eg, “worsening of…”).
If a subject h as a degenerat ive concurrent condition (eg, cataracts, rheumatoid arthritis), 
worsening of the condit ion should only be captured as an AE if occurring to a greater extent to 
that which would be expected. Again, Invest igators should ensure that the AE term recorded 
captures the change in the condit ion (eg, “worsening of…”).
Worsening of AEs:
If the subject experiences a worsening or complicatio n of an AE aft er the first administration of 
study  medicat ion or after any  change in study  medicat ion, the worsening or com plicat ion 
shoul d be recorded as a new AE. Invest igators should ensure that the AE term recorded 
captures the change in the condit ion (eg, “worsening of…”).
Changes in severit y of AEs:
If the subject experiences a change in the severit y of an AE that is not associated with a change 
in study  medicati on, the event shoul d be captured once with the maximum severit y recorded.
Prepl anned surgeries or procedures:
Prepl anned procedures (surgeries or therapies) that were scheduled prior to signing of 
inform ed consent are not considered AEs. However, if a preplanned procedure is performed 
early (eg, as an emergency) due to a worsening of the pre -exist ing condit ion, the worsening o f 
the condi tion shoul d be captured appropriately  as an AE. Com plicati ons resul ting from any 
planned surgery  should be reported as AEs.
Elect ive surgeries or procedures:
Elect ive procedures performed where there is no change in the subject’s medical condit ion 
shoul d not be recorded as AEs but should be documented in the subject’s source d ocum ents. 
Com plicat ions result ing from an elect ive surgery should be reported as AEs.
Overdose:
An overdose is defined as a known deliberate or accidental administration of investigational 
drug, to or by  a study  subject, at a dose above that which is assig ned to that individual subject 
according to the study protocol. It is up to the Investigator or the reporting physician to decide 
whether a dose is to be considered an overdose, in consultation wit h the Sponsor.
All cases of overdose (with or without assoc iated AEs) will be documented on an Overdose 
page of the (e)CRF, in order to capture this important safet y information consistent ly in the 
Mobocertinib
Study No. TAK -788-1008 Page 50of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALdatabase. AEs associated with an overdose will be documented on AE CRF(s) according to 
Secti on  10.0.
Serious adverse events (SAEs) of overdose should be reported according to the procedure 
outlined in Sect ion  10.2.6 .
In the event of drug overdose, the subject should be treated symptomat ically.
10.1.1 SAEs
An SAE is defined as any untoward medical occurrence that at any  dose:
1.Results in DEATH.
2.Is LIFE THREATENIN G.
The term “life threatening” refers to an event in which the subject was at risk of death at the 
time of the event; it does not refer to an event that hypothetically might have caused death 
if it were m ore severe.
3.Requi res inpat ient HOSPITALIZATION or pr olongati on of  exist ing hospitalizat ion.
4. Results in persistent or significant DISABILITY/INCAPACITY.
5.Is a CONGENITAL ANOMALY/BIRTH DEFECT.
6.Is an IMPORTANT MEDICAL EVENT that satisfies any of the fo llowing:
May require intervent ion to prevent items 1 through 5 above.
May expose the subject to danger, even though the event is not immediately life 
threatening or fatal or does not result in hospitalization.
AEs that fulfill 1 or more of the ser ious criteria above are to be considered SAEs and should be 
reported and fo llowed up in the same manner (see Sections 10.1.1 and 10.2.6.3 ).
Mobocertinib
Study No. TAK -788-1008 Page 51of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALTable10.a Takeda Medically Significant AE List 
Term
Acute respiratory failure/acute respiratory 
distress syndromeHepatic necrosis
Acute liver failure
Torsade de pointes / ventricular fibrillation / 
ventricular tachycardiaAnaphy lactic shock
Acute renal failure
Malignant hypertension Pulmonary hypertension
Convulsive seizures Pulmonary fibrosis
Agranulocytosis Confirmed or suspected endotoxin shock
Aplastic anemia Confirmed or suspected transmission of infectious agent by 
a medicinal productToxic epidermal necrolysis/
Stevens -Johnson syndrome Neuroleptic malignant syndrome / malignant hyperthermia
Spontaneous abortion / stillbirth and fetal death
AEs that fulfill 1 or more of the serious criteria above are to be considered SAEs and should be 
reported and fo llowed up in the same manner (see Sections  10.1 and 10.1.1 ).
10.1.2 Special Interest AEs
There are no AEs of Special Interest for this study .
10.2 AE Procedures
10.2.1 Assigning Severity/Intensity of AEs
In thi s study , intensi ty for each AE, including any  laboratory  abnorm ality, will be determined 
using the National Cancer Inst itute, Commo n Termino logy Criteria f or Adverse Events (NCI 
CTCAE), versio n 5.0, dated 27 November 2017 [ CTCAE 2017]. Cl arificati on shoul d be m ade 
between an SAE and an AE that is considered severe in intensit y (Grade 3 or 4) because the terms 
serious and severe are NOT synonymous. The general term severe is often used to describe the 
intensity (severi ty) of a specific event; the event itself, however, may  be of  relatively minor 
medical significance (such as a Grade 3 headache). This is NOT the same as serious , which is 
based on subject/event outcome or act ion criteria described above and is usually  associated wi th 
events that pose a threat to a subject’s life or abilit y to functi on. A severe AE (Grade 3 or 4) does 
not necessarily need to be considered serious. For example, a white blood cell count of 1000/m m3
to <2000/mm3is considered Grade 3 (severe) but may not be considered serious. Seriousness (not 
intensity) serves as a guide for defining regulatory  reporting obligations.
Mobocertinib
Study No. TAK -788-1008 Page 52of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIAL10.2.2 Assigning Causality of AEs
The rel ationship of each AE to study  medicati on(s) will be assessed using the fo llowing 
categori es:
Related: An AE that fo llows a reasonable temporal sequence fro m administration of a 
drug (including the course after withdrawal o f the drug), or for whi ch a causal  
relationship is at least a reasonable possibil ity, ie, the relati onship cannot be 
ruled out , although factors other than the drug, such as underlying diseases, 
complicat ions, conco mitant drugs and concurrent treatments, may also be 
responsible.
Not Rel ated: An AE that does not follow a reasonable tem poral  sequence fro m ad ministration 
of a drug and/or that can reasonably be explained by  other factors, such as 
underlying diseases, complicat ions, conco mitant medi cations and concurrent 
treatm ents.
10.2.3 Start Date 
The start date of the AE is the date that the first signs/symptoms were noted by  the subject and/or 
Invest igator.
10.2.4 End Date 
The end date of the AE is the date at which the subject recovered, the event resolved but with 
sequelae or the subject died.
10.2.5 Outcome 
Recovered/reso lved –subject returned to fi rst assessment status with respect to the AE.
Recovering/resolving –the intensit y is lowered by  one or m ore stages: the diagnosis has or 
signs/symptom s have alm ost disappeared; the abnormal laboratory  value improved, but has 
not returned to the normal range or to the baseline value; the subject died fro m a cause other 
than the particular AE with the condit ion rem aining “recovering/resolving.”
Not recovered/not resolved –there is no change in the diagnosis, signs or symptoms; the 
intensity of the di agno sis, signs/symptoms or laboratory  value on the l ast day  of the observed 
study peri od has beco me worse than when it started; is an irreversible congenital ano maly; the 
subject died fro m another cause with the particular AE state remaining “Not recovered/not
resolved.”
Recovered/ Reso lved wit h sequelae –the subject recovered from an acute AE but was left with 
perm anent/si gnificant impairment (eg, recovered from a cardiovascular accident but with 
some persisting paresis).
Fatal  –an AE that is considered as t he cause of death.
Mobocertinib
Study No. TAK -788-1008 Page 53of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALUnknown –the course of the AE cannot be fo llowed up due to hospi tal change or residence 
change at the end of the subject’s participation in the study .
10.2.6 Collection and Reporting of AEs, SAEs, Special Interest AEs, and Abnormal LFTs
10.2.6.1 Collec tion Period
Collect ion of AEs (ie, AEs, SAEs, Special Interest AEs, and Abnormal LFTs) will co mmence at 
the time the subject signs the informed consent. Routine co llection of AEs will cont inue until the 
follow-up phone call 30 days (± 2 day s) after mobocer tinib dosing. For subjects who discont inue 
prior to the administration o f mobocertinib , AEs will be fo llowed unt il the subject discont inues 
study  participati on. 
10.2.6.2 Reporting AEs
At follow-up, the Investigator will assess whether any subject ive AEs have occur red. A neutral 
question, such as “How have y ou been feeling since y our last visit ?” may be asked. Subjects may  
report AEs occurring at any other time during the study. Subjects experiencing an SAE prior to the 
first exposure to invest igational product must be monitored until the symptoms subside and any 
clinically relevant changes in laboratory values have returned to Baseline or there is a satisfactory 
explanat ion for the change. Nonserious AEs that begin prior to the first exposure to invest igational 
product, related or unrelated to the study procedure, need not be fo llowed-up for the purposes of 
the protocol.
All subjects experiencing AEs, whether considered associated with the use of the study medicat ion 
or not, m ust be m onitored until the symptoms subsi de and any clinically  relevant changes in 
laboratory  values have returned to Baseline or until there is a sat isfactory  explanati on for the 
changes observed. All AEs will be documented in the AE page of the CRF, whether or not the 
Invest igator concludes tha t the event is related to the drug treatment. The fo llowing informat ion 
will be documented for each event:
Event term .
Start and end date and time.
Pattern of AE (frequency).
Severit y/Intensi ty.
Causalit y (Invest igator’s opinio n of the causal relationship between the event and 
administration of study  drug[s]).
Action taken with Study  drug.
Outcom e of event.
Seriousness.
Mobocertinib
Study No. TAK -788-1008 Page 54of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIAL10.2.6.3 Reporting SAEs
When an SAE occurs through the AE collection period it should be reported according to the 
procedure outlined below:
A Taked a SAE form must be completed, in English and signed by the Invest igator immediately or 
within 24 hours of first onset or notification of the event. The informat ion should be co mpleted as 
fully as possible but contain, at a minimum:
A short descript ion of t he event and the reason why  the event i s categori zed as serious.
Subject identificat ion number.
Invest igator’s name.
Nam e of the study  medicat ion(s).
Causalit y assessment.
The SAE form should be transmitted within 24 hours to the attention of the contact listed in 
Secti on  14.1.1 .
Any SAE spontaneously reported to the Invest igator fo llowing the AE collect ion period should be 
reported to the Sponsor if considered related to study  parti cipat ion.
Reporting of SAEs that begin before first administration of investigational product will fo llow the 
same procedure for SAEs occurring on treatme nt.
SAE Follow -Up
If informat ion is not available at the time o f the first report becomes available at a later date, the 
Invest igator should complete a fo llow-up SAE form or provide other written documentation and 
fax it immediately wit hin 24 hours of rece ipt. Copies of any relevant data from the hospital notes 
(eg, ECGs, laboratory  tests, di scharge summary, postmortem results) should be sent to the 
addressee, if requested.
All SAEs should be fo llowed up unt il reso lution or perm anent outcome of the event. The timelines 
and procedure for follow -up reports are the same as those for the init ial report.
10.2.6.4 Reporting Special Interest AEs 
Not applicable
10.2.6.5 Reporting of Abnormal Liver Function Tests
Healthy-Matched Subjects
If a healt hy subject has elevated ALT ≥3x ULN with concurrent elevated total bilirubin >2x ULN 
orelevated internat ional norm alized rati o (INR) >1.5, contact the sponsor’s medical mo nitor 
within 24 hours. 
For any  healthy subject with ALT ≥3x ULN and total bilirubin >2x ULN or INR >1.5x ULN for 
Mobocertinib
Study No. TAK -788-1008 Page 55of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALwhich an al ternat ive et iology has not been found, report the event as an SAE (Section 10.2.6.3 ) 
and contact the sponsor immediately.
Hepati c Impairment Su bjects
If a HI subject has elevated ALT ≥6x ULN wit h concurrent elevated total bilirubin >4x ULN or
elevated INR >3x ULN, contact the sponsor’s medical mo nitor wi thin 24 hours. 
For any HI subject with ALT ≥6x ULN and total bilirubin >4x ULN or INR >3x ULN for which an 
alternat ive etio logy has not been found, report the event as an SAE (Section  10.2.6.3 ) and contact 
the sponsor immediately .
10.2.7 Safety Re porting to Investigators, IRBs or IECs, and Regulatory Authorities 
The Sponsor will be responsible for reporting all suspected unexpected serious adverse react ions 
(SUSARs) and any other applicable SAEs to regulatory  authori ties, Investi gators and IRBs or
IECs, as applicable, in accordance with nat ional regulat ions in the countries where the study  is 
conducted. Relat ive to the first awareness of the event by/or further provisio n to the Sponsor or 
Sponsor’s designee, SUSARs will be submitted within 7 days f or fatal and life -threatening events 
and 15 days for other serious events, unless otherwise required by nat ional regulat ions. The 
Sponsor will also prepare an expedited report for other safety issues where these might materially 
alter the current benefit -risk assessment of an investigat ional medicinal product or that would be 
sufficient to consider changes in the investigat ional medicinal products administration or in the 
overall conduct of the Study. The invest igational site al so will forward a copy  of allexpedi ted 
reports to his or her IRB or IEC in accordance wit h national regulat ions.
10.2.8 Procedures for Reporting Product Complaints or Medication Errors (Including 
Overdose)
A product complaint is a verbal, written, or electronic expression that implies dissa tisfact ion 
regarding the identit y, strength, puri ty, quali ty, or s tabilit y of a drug product. Individuals who 
ident ify a potential product complaint situat ion shoul d immediately report this via the phone 
numbers or email addresses provided below.
A medicat ion error is a preventable event that involves an ident ifiable pat ient and l eads to 
inappropriate medicat ion use, which may  resul t in patient harm. Whereas overdoses and 
underdoses const itute medication errors, doses missed inadvertent ly by a pat ient do not. 
Individuals who ident ify a potential medicat ion error (including overdose) situation should 
immediately  report thi s via the phone numbers or email addresses provided below.
Product Call Center Phone Number Email Fax
Mobocertinib Dohmen Life Science 
Services, or DLSS 
(formerly  known as 
MedComm)1-844-662-8532 
Non-toll-free number: 
1-510-740-1273 GlobalOncologyMedinfo@
takeda.com 1-800-881-
6092
Product complaints and medicat ion errors in and of themselves are not AEs. If a product complaint  
or a m edicat ion error results in an SAE, the SAE should be reported.
Mobocertinib
Study No. TAK -788-1008 Page 56of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIAL11.0 STATISTICAL METHODS
11.1 Statistical and Analytical Plans
Detailed methodology  for summary  and stati stical analyses o f the data collected in this study  will 
be docum ented in a stati stical analysis plan (SAP). The SAP will be prepared by Celerion and 
agreed upon with the Sponsor. This document may modify the plans outlined in the protocol; 
however, any major modificat ions of the primary endpo ints definit ion and/or its analysis will also  
be reflected in a protocol amendment. Addit ional statistical analyses other than those described in 
this secti on may  be perf ormed if deemed appropriate.
11.1.1 Analysis Sets
11.1.1.1 Pharmacokinetic Set
Samples fro m all subjects will be assayed even if the subjects do not complete the study . All 
subjects who comply sufficient ly wit h the protocol and display an evaluable PK profile 
(eg,exposure to treatm ent, availabilit y of measurements and absence o f major protocol vio lations) 
will be included in the statistical analyses. Any subject who experiences emesis wit hin 8 hours 
post dosing wit h mobocertinib will be excluded in the final data analysis.
11.1.1.2 Safety Set
All subjects who received the study  drug will  be incl uded in the safet y evaluat ions.
11.1.1.3 Pharmacodynamic Set
Not applicable.
11.1.2 Analysis of Demography and Other Baseline Characteristics
Continuous demographic data (ie, age, weight, height, and BMI) will be listed and summarized 
using appropriate summary statist ics. Categori cal dem ographic data (i e, gender, race, and 
ethnicit y) will also be li sted and tabulated.
11.1.3 Pharmacokinetic Analysis
PK parameters for mobocertinib and metaboli tes (AP32960 and AP32914) in plasma will be 
calculated as described in Sect ion  9.3.1.1 , and outlined in the SAP.
The ln -transform ed of the combined mo lar unbound C max,uAUC last,u, and AUC ∞,u, for mobocertinib
and its metabolites (AP32960 and AP32914) will be compared between hepatic impairment and 
the healt hy arms using an ANOVA model. 
The ANOVA model will include hepat ic impairment versus normal condit ions as a fixed effect 
and subject nested within group as a random effect. Each ANOVA analysis will calculate the 
LSM, the difference between group LSMs, and the sta ndard error associated with the difference. 
Residual, subject nested within group, and intersubject variance will be reported. Ratio of LSM 
Mobocertinib
Study No. TAK -788-1008 Page 57of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALand 90% CI will be calculated using the exponent ial function of the difference between group 
LSMs fro m the analysis on the l n-transformed combined mo lar unbound C max,uAUC last,u, and 
AUC ∞,u,for mobocertinib , AP32960, and AP32914. 
The same analysis will be repeated for each analyt e (mobocertinib , AP32960, and AP32914) 
separately  and will  be perform ed on total  PK parameters as well (C max, AUC last, and AUC ∞).
11.1.4 Pharmacodynamic Analysis 
Not applicable.
11.1.5 Safety Analysis
All safet y data will be populated in the individual CRFs. 
Dosing dates and t imes will be listed by subject.
Quant itative safet y data as well as the dif ference to baseline, when appropriate, will be 
summarized using the appropriate descriptive statistics.
11.1.5.1 AEs
AEs will be coded using the most current version of Medical Dict ionary for Regulatory  Activit ies 
(MedDRA®) available at Celerio n and summarized by popul ation for the number of subjects 
reporting the TEAE and the number of TEAEs reported. A by -subject AE data list ing including 
verbat im term, coded term, treatment, severit y, and rel ationship to treatment will be provided.
11.1.5.2 Clinical Laboratory Evaluation
Clinical laboratory  resul ts will  be summarized by  popul ation and point of time of co llection and a 
shift table describing out of normal range shifts will be provided.
11.1.5.3 Vital Signs
Vital signs assessments will be summarized by  popul ation and point of time of collection.
11.1.5.4 Other Safety Parameters
Physical examinat ion findings will be presented in the data list ings.
ECGs will be summarized by  popul ation and point of time o f collect ion.
Medical history , and concurrent condit ions will be coded using the MedDRA®andconco mitant 
medicat ions will be coded using the World Healt h Organizat ion drug dict ionary and will  be listed 
by subject.
11.2 Interim Analysis and Criteria for Early Termination
An informal preliminary  PK data analysis will be performed on approximately  3 moderate HI 
subjects and 3 healt hy matched subjects who completed study  procedures up to Day 10 and m ay 
additionally  leverage histori cal control  PK data in healt hy subjects to gain an init ial estimate of 
Mobocertinib
Study No. TAK -788-1008 Page 58of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALeffect of moderate HI on the PK of mobocerti niband its active m etabo lites (AP32960 and 
AP32914). These preliminary  data al ong wi th safety  data will gui de the deci sion to enroll  the 
severe HI arm (for example, a decisio n will be made to dose the severe HI group at the same dose 
as the m oderate HI arm, a reduced dose, or to not dose this arm).
There are no predetermined criteria for early terminat ion of the study .
11.3 Determination of Sample Size
The pl anned sam ple size of 8 subjects in each hepatic funct ion arm  represents a si ze that is 
considered adequate to provid e a descript ive characterizat ion of the PK of mobocerti niband its 
active metabo lites in subjects with moderate or severe hepat ic impairment compared to healthy 
subjects wi th normal  hepatic function.
At least 24 subjects will be enrolled into 3 arms (appro ximately 8 subjects in each arm) in the 
study . The target numbers for the matched- healt hy subjects with normal hepat ic function are 
8 subjects; however up to 16 healthy subjects may be enrolled into Arm 3 if it is not feasible to 
match the first 8 healthy subjects into both Arms 1 and 2.
Mobocertinib
Study No. TAK -788-1008 Page 59of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIAL12.0 QUALITY CONTROL AND QUALITY ASSURANCE
12.1 Study -Site Monitoring Visits
Moni toring visit s to the study  site will  be made peri odically  during the study  to ensure that all 
aspects of the protocol are fo llowed. Source documents wil l be reviewed for verificat ion of data 
recorded on the CRFs. Source documents are defined as original documents, data, and records. 
The Investigator and study  site guarantee access to source documents by  the Sponsor or i ts 
designee (Clinical Research Organ ization) and by the IRB or IEC.
All aspects of the study  and i ts docum entati on will be subject to review by the Sponsor or the 
Sponsor’s designee (as lo ng as blinding is not jeopardized), including but not limited to the 
Invest igator’s Binder, study  drug, subject medical records, informed consent documentation, and 
review of CRFs and associated source documents. It is important that the Invest igator and other 
study  personnel are available during the monitoring visits and that sufficient time is devoted to t he 
process.
12.2 Protocol Deviations
The Investigator should not deviate fro m the protocol, except where necessary to eliminate an 
immediate hazard to Study subjects. Should other unexpected circumstances arise that will require 
deviat ion from protocol -specifie d procedures, the Investigator should consult with the sponsor or 
designee (and IRB or IEC, as required) to determine the appropriate course of action. There will be 
no exempt ions (a prospectively approved deviat ion) from the inclusio n or exclusio n criteria.
Significant deviat ions include, but are not limited to, those that invo lve fraud or misconduct, 
increase the healt h risk to the subject, or confound interpretation of primary study  assessment. 
12.3 Quality Assurance Audits and Regulatory Agency Inspections
The study  site also may  be subject to qualit y assurance audi ts by  the Sponsor or designees. In this 
circumstance, the Sponsor -designated auditor will contact the site in advance to arrange an 
auditing visit. The auditor may ask to visit the facilit ies wher e laboratory  samples are collected, 
where the medication is stored and prepared, and any other facilit y used during the study . In 
addition, there is the possibilit y that this study may be inspected by regulatory agencies, including 
those of foreign governm ents (eg, the FDA, the United Kingdo m Medicines and Healthcare 
products Regulatory  Agency , the Pharmaceut icals and Medical Devices Agency o f Japan). If the 
study  site is contacted for an inspect ion by a regulatory  body , the Sponsor should be notified 
immed iately. The Invest igator guarantees access for qualit y assurance auditors to all study  
docum ents as described in Sect ion  12.1.
Mobocertinib
Study No. TAK -788-1008 Page 60of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIAL13.0 ETHICAL ASPECTS OF T HE STUDY
This st udy will be conducted wi th the highest respect for the individual participants (ie, subjects) 
according to the protocol, the ethical principles that have their origin in the Declaration o f 
Helsinki, and the Internat ional Council on Harmonisation (ICH) Harm onised Tri partite Gui deline 
for GCP. Each Invest igator will conduct the study according to applicable local or regional 
regul atory  requi rements and align his or her conduct in accordance with the “Responsibilit ies of 
the Invest igator” that are listed in  Appendix A. The principles of Helsinki are addressed through 
the protocol and through appendices containing requirements for informed consent and 
Invest igator responsibilit ies.
13.1 IRB and/or IEC Approval
IRBs and IECs must be constituted according to the applicable state and federal/local requirements 
of each participat ing region. The Sponsor or designee will require documentation noting all names 
and tit les of members who make up the respective IRB or IEC. If any member of the IRB or IEC 
has di rect parti cipat ion in this study , written notification regarding his or her abstinence fro m 
voting must also be obtained. Those Americas sites unwilling to provide names and tit les ofall 
members due to privacy  and conflict of interest concerns should instead provide a Federal Wide 
Assurance Number or comparable number assigned by the Department of Health and Human 
Services.
The Sponsor or designee will supply  relevant documents for su bmissio n to the respective IRB or 
IEC for the protocol’s review and approval. This protocol, the Invest igator’s Brochure, a copy o f 
the informed consent form, and, if applicable, subject recruit ment materials and/or advertisements 
and other documents requi red by all applicable laws and regulations, must be submitted to a 
central  or local IRB or IEC for approval. The IRB’s or IEC’s written approval of the protocol and 
subject informed consent must be obtained and submitted to the Sponsor or designee before 
commencement of the study  (ie, before shipment of the Sponsor -supplied drug or study  specific 
screening activit y). The IRB or IEC approval must refer to the study  by exact protocol tit le, 
number, and versio n date; ident ify versio ns of other documents (eg, inform ed consent form ) 
reviewed; and state the approval date. The Sponsor will ship drug/notify site once the Sponsor has 
confirmed the adequacy of site regulatory  docum entati on and, when applicable, the Sponsor has 
received permissio n from competent author ity to begin the Study . Unt il the site receives 
drug/notificat ion no protocol activit ies, including screening, may occur.
Sites m ust adhere to all requirements stipulated by  their respect ive IRB or IEC. This may include 
notification to the IRB or IEC regar ding protocol amendments, updates to the informed consent 
form, recrui tment m aterials intended for viewing by  subjects, l ocal safety  reporti ng requirements, 
reports and updates regarding the ongoing review of the study  at intervals specified by  the 
respect ive IRB or IEC, and submissio n of the Investigator’s final status report to IRB or IEC. All 
IRB and IEC approvals and relevant documentation for these items must be provided to the 
Sponsor or i ts desi gnee.
Subject incentives should not exert undue influenc e for participat ion. Payments to subjects must 
be approved by the IRB or IEC and Sponsor.
Mobocertinib
Study No. TAK -788-1008 Page 61of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIAL13.2 Subject Information, Informed Consent, and Subject Authorization
Written consent documents will embody  the elements of informed consent as described in the 
Declaratio n of Helsinki and the ICH Guidelines for GCP and will be in accordance with all 
applicable laws and regulations. The informed consent form, subject authorizat ion form (if 
applicable), and subject informat ion sheet (if applicable) describe the planned and p ermitted uses, 
transfers, and disclo sures of the subject’s personal and personal healt h informat ion for purposes of 
conducting the study. The informed consent form and the subject informat ion sheet (if applicable) 
further explain the nature of the study, i ts object ives, and potential risks and benefit s, as well as the 
date informed consent is given. The informed consent form will detail the requirements of the 
participant and the fact that he or she is free to withdraw at any  time wi thout giving a reason an d 
without prej udice to hi s or her further m edical care.
The Investigator is responsible for the preparation, content, and IRB or IEC approval of the 
inform ed consent form  and, if applicable, the subject authorization form. The informed consent 
form, subjec t authorizat ion form (if applicable), and subject information sheet (if applicable) must 
be approved by both the IRB or IEC and the Sponsor prior to use.
The informed consent form, subject authorizat ion form  (if applicable), and subject informat ion 
sheet ( if applicable) must be written in a language fully co mprehensible to the prospective subject. 
It is the responsibilit y of the Invest igator to explain the detailed elements of the informed consent 
form, subject authorizat ion form (if applicable), and subject informat ion sheet (if applicable) to the 
subject. Information should be given in both oral and written form whenever possible and in the 
manner deemed appropriate by the IRB or IEC. In the event the subject is not capable of rendering 
adequate written in formed consent, then the subject’s legally  acceptable representative may 
provi de such consent for the subject in accordance with applicable laws and regulat ions.
The subject, or the subject’s legally acceptable representative, must be given ample opportuni ty to: 
(1) inquire about details o f the study, and (2) decide whether or not to participate in the study. If the 
subject, or the subject’s legally acceptable representative, determines he or she will part icipate in 
the study , then the informed consent form and subject authorizat ion form (if applicable) m ust be 
signed and dated by  the subject, or the subject’s legally  acceptable representative, at the time of 
consent and prior to the subject entering into the study . The subject or the subject’s legally 
accep table representative should be instructed to sign using their legal names, not nicknames, 
using blue or black ballpo int ink. The Invest igator must also sign and date the informed consent 
form and subject authorizat ion (if applicable) at th e time of consent and prior to subject entering 
into the study ; however, the Sponsor may allow a designee of the Invest igator to sign to the extent  
permitted by  applicable law.
Once signed, the original informed consent form, subject authorization form (if applicable), and
subject informat ion sheet (if applicable) will be stored in the Investigator’s site file. The 
Invest igator must document the date the subject signs the informed consent in the subject’s 
medical record. Copies of the signed informed consent form, the signe d subject authorization for m 
(if applicable), and subject informat ion sheet (if applicable) shall be given to the subject.
Mobocertinib
Study No. TAK -788-1008 Page 62of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALAll revised informed consent forms must be reviewed and signed by relevant subjects or the 
relevant subject’s legally  acceptable repr esentative in the same manner as the original informed 
consent. The date the revised consent was ob tained shoul d be recorded in the subject’s medical 
record, and the subject should receive a copy  of the revised informed consent form.
13.3 Subject Confidentialit y
The Sponsor and designees affirm and upho ld the principle of the subject’s right to protection 
against invasio n of privacy. Throughout this study , a subject’s source data will only be linked to 
the Sponsor’s clinical study  database or documentation via a unique i dentificat ion number. As 
permitted by all applicable laws and regulat ions, limited subject attributes, such as sex, age, or date 
of birth, and subject init ials may be used to verify the subject and accuracy o f the subject’s unique 
ident ificat ion number.
To comply wit h ICH Guidelines for GCP and to verify co mpliance with this protocol, the Sponsor 
requi res the Invest igator to permit its monitor or designee’s monitor, representatives from any 
regul atory  authori ty (eg, FDA, Medi cines and Heal thcare pr oducts Regul atory  Agency, 
Pharmaceut icals and Medical Devices Agency), the Sponsor’s designated auditors, and the 
appropriate IRBs and IECs to review the subject’s original medical records (source data or 
docum ents), including, but not limited to, laborato ry test result reports, ECG reports, admissio n 
and discharge summaries for hospital admissio ns occurring during a subject’s study participation, 
and autopsy  reports. Access to a subject’s original medical records requires the specific 
authori zation of the subject as part of the informed consent process (see Section 13.2).
Copi es of  any subject source documents that are provided to the Sponsor must have certain 
personally ident ifiable informat ion rem oved (ie, subject name, address, and other ident ifier fields 
not collected on the subject’s CRF).
13.4 Publication, Disclosure, and Clinical Study Registration Policy
13.4.1 Publication and Disclosure
The Investigator is obliged to provide the Sponsor with complete test results and all data derived 
by the Invest igator fro m the study . During and after the study , only  the Sponsor m ay make study  
inform ation available to other study  Invest igators or to regulatory  agencies, exc ept as requi red by  
law or regul ation. Except as otherwise allowable in the clinical study  site agreement, any  public 
disclosure (including publicly accessible websites) related to the protocol or study  resul ts, other 
than study  recrui tment m aterials and/or advertisements, is the sole responsibilit y of the Sponsor.
The Sponsor may publish any data and information fro m the study (including data and informat ion 
generated by  the Invest igator) without the consent of the Invest igator. Manuscript authorship for 
any peer -reviewed publicat ion will appropriately reflect contribut ions to the production and 
review of the document. All publicat ions and presentations must be prepared in accordance with 
this secti on and the Clinical Study  Site Agreement. In the event of an y discrepancy  between the 
protocol  and the Clinical Study  Site Agreement, the Clinical Study  Site Agreement will prevail.
Mobocertinib
Study No. TAK -788-1008 Page 63of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIAL13.4.2 Clinical Study Registration 
In order to ensure that informat ion on clinical study reaches the public in a t imely manner and to 
complywith applicable laws, regulat ions and guidance, Takeda will, at a minimum register all 
intervent ional clinical study  it Sponsors any where in the worl d on ClinicalTrials.gov and/or other 
publicly  accessible websites before start of study , as defined in Tak eda Policy/Standard . Takeda 
contact informat ion, along with Investigator’s city, state (for Americas Invest igators), country, and 
recrui ting status will be registered and available for public viewing. 
For some registries, Takeda will assist callers in lo cating study  sites cl osest to thei r homes by 
provi ding the Invest igator name, address, and phone number to the callers request ing study  
inform ation. Once subjects receive Investigator contact informat ion, they  may call  the si te 
requesting enrollment into th e study . The invest igative sites are encouraged to handle the study 
inquiries according to their established subject screening process. If the caller asks addit ional 
questions bey ond the topic of study  enro llment, th ey shoul d be referred to the Sponsor.
Any Invest igator who objects to the Sponsor providing this informat ion to callers must provide the 
Sponsor with a written notice requesting that their informat ion not be listed on the registry  site.
13.4.3 Clinical Study Results Disclosure 
Takeda will post the results of clinical study on ClinicalTrials.gov or other publicly accessible 
websites, as required by Takeda Policy/Standard, applicable laws and/or regulat ions.
13.5 Insurance and Compensation for Injury
Each subject in the study  must be insured in accordance with the regulations applicable to the site 
where the subject is part icipating. If a local underwriter is required, then the Sponsor or Sponsor’s 
designee will obtain clinical study  insurance against the risk o f injury to study  subjects. Refer to 
the study site agreement regarding the Sponsor’s policy on subject compensat ion and treatment for 
injury . If the Investigator has quest ions regarding this po licy, he or she should contact the Sponsor 
or Sponsor’s designee.
Mobocertinib
Study No. TAK -788-1008 Page 64of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIAL14.0 ADMINISTRATIVE AND REFERENCE INFORMATION
14.1 Administrative Information
14.1.1 Study Contact Information 
Contact Type / Role Contact
Serious adverse event and pregnancy reporting SAE Reporting Contact Information
Cognizant
US and Canada
Toll-free fax #: 1 -800-963 -6290
E-mail: takedaoncocases@cognizant.com
Please refer to Safety Management Plan.
Mobocertinib
Study No. TAK -788-1008 Page 65of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIAL14.1.2 Investigator Agreement 
I confirm that I have read and that I understand this protocol, the Invest igator’s Brochure and any 
other product information provided by the Sponsor. I agree to conduct this study  in accor dance 
with the requirements of this protocol and also to protect the rights, safet y, privacy, and well -being 
of study  subjects in accordance with the following:
The ethical principles that have their origin in the Declaration of Helsinki.
ICH, E6 [R2] GCP: Consolidated Gui deline.
All applicable laws and regulat ions, including, without limitat ion, data privacy laws and 
regul ations.
Regulatory  requi rements for reporting SAEs defined in Section 10.2.7 of this protocol .
Terms outlined in the study  site agreement.
Responsibilit ies o f the Invest igator (Appendix B).
I further authorize that my  personal informat ion may be processed and transferred in accordance 
with the uses contem plated in  Appendix Dof this protocol .
Signature of Investigator Date
Invest igator Name (print or ty pe)
Invest igator’s Tit le
Locati on of  Facilit y (Ci ty, State/Provence)
Locati on of  Facilit y (Country )
Mobocertinib
Study No. TAK -788-1008 Page 66of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIAL14.1.3 Study -Related Responsibilities 
The Sponsor will perform all study -related acti vities wi th the excepti on of  those i dentified in the 
Study -Related Responsibilit ies template. The vendors i dentified for specific study -related 
activit ies will perform these act ivities in full or in partnership wi th the Sponsor.
14.1.4 List of Abbreviations
AE Adverse event
ALP Alkaline phosphatase
ALT Alanine aminotransferase
ANOVA Analy sis of variance
AST Aspartate aminotransferase
AUC Area under the concentration -time curve
AUC last Area under the concentration -time curve, from time 0 to the last observed non -zero 
concentration total
AUC last,u Area under the concentration -time curve from time 0 to time t the last observed non -zero 
concentration unbound
AUC  Area under the concentration -time curve, from time 0 extrapolated to infinity total
AUC ,u Area under the concentration -time curve, from time 0 extrapolated to infinity unbound
BMI Body mass index
bpm Beats per minute
Cav Average concentration 
CFR Code of Federal Regulations
CI Confidence interval
CL/F Apparent clearance after extravascular administration total
CL u/F Apparent clearance after extravascular administration unbound
cm Centimeter
Cmax Maximum observed concentration total
Cmax,u Maximum observed concentration unbound
COVID -19 Novel Corona Virus Vaccine 2019
CRA Clinical Research Associate
CRF Case report form
CRU Clinical Research Unit
CYP Cytochrome P450
DNA Deoxyribonucleic acid 
ECG Electrocardiogram
EGFR Epidermal growth factor receptor 
FSH Follicle stimulating hormone
g Gram
GCP Good Clinical Practice
GMR Geometric mean ratio
HBsAg Hepatitis B surface antigen
HCV Hepatitis C virus 
HER2 Human epidermal growth factor 2
Mobocertinib
Study No. TAK -788-1008 Page 67of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALHI Hepatic impairment
HIV Human immunodeficiency virus
IB Investigator’s Brochure
ICF Informed Consent Form
ICH International Council for Harmonisation
IEC Independent Ethics Committee
IRB Institutio nal Review Board
kg Kilogram
LFT Liver function test
LSM Least -squares mean
m2Meters squared
MedDRA®Medical Dictionary for Regulatory Activities®
mg Milligram
min Minute
mL Milliliter
mmHg Millimeter of mercury
msec Millisecond
NSCLC Non–small cell lung cancer
P-gp P-glycoprotein
PFT Pulmonary Function Test(s)
PK Pharmacokinetic(s)
QD Once daily
QTcF QT interval corrected for heart rate using Fridericia’s formula
RNA Ribonucleic acid
SAE Serious adverse event
SAP Statistical analysis plan
SUSAR Suspected unexpected serious adverse reaction
t½ Apparent first -order terminal elimination half -life
tmax Time to reach C max
TEAE Treatment -emergent adverse event
TKI Tyrosine kinase inhibitor
ULN Upper limit of normal
US United States
USA United States of America
Vz/F Apparent volume of distribution after extravascular administration total
Vz,u/F Apparent volume of distribution after extravascular administration unbound
WT Wild-ty pe
λz Apparent first order terminal elimination rate constant
Mobocertinib
Study No. TAK -788-1008 Page 68of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIAL15.0 DATA HANDLING AND RE CORDKEEPING
The full details of procedures for data handling will be documented in the Data Management P lan.
15.1 CRFs (Electronic and Paper)
The Sponsor or its designee will supply invest igative sites with access to CRFs. The Sponsor or its 
designee will train appropriate site staff in the use of the CRF. These forms are used to transmit the 
inform ation collecte d in the performance of this study  to the Sponsor and regulatory  authori ties. 
CRFs must be completed in English.
After complet ion of the entry process, computer logic checks will be run to identify items, such as 
inconsistent dates, missing data, and quest ionable values. Queries may  be issued by Takeda 
personnel (or designees) and will be answered by the site. 
Correcti ons are recorded i n an audit trail that captures the old informat ion, the new informat ion, 
ident ificat ion of the person making the correctio n, the date the correction was made, and the reason 
for change. Reasons for si gnificant correcti ons shoul d addi tionally be included. 
The principal Invest igator must review the CRFs for completeness and accuracy and must sign and 
date the appropriate CRFs as indicated. Furthermore, the Investigator must retain full 
responsibilit y for the accuracy  and authent icity of all data entered on the CRFs .
After the lock of the clinical study database, any change of, modificat ion of, or addit ion to the data 
on the CRF s shoul d be m ade by  the Invest igator/designee with use o f change and modificat ion 
records of the CRFs. The Principal Invest igator must review the data change for completeness and 
accuracy , and m ust si gn and date . 
CRFs will be reviewed for completeness and acceptabilit y at the study  site during peri odic visi ts 
by study  monitors. The Sponsor or i ts desi gnee will  be permi tted to revi ew the subject’s medical 
and hospital records pertinent to the study  to ensure accuracy  of the CRFs. The com pleted CRFs 
are the sole property  of the Sponsor and should not be made available in any form to third parties, 
except for authorized representatives of appropriate governmental healt h or regulatory authorities, 
without wri tten permissio n of the Sponsor.
15.2 Record Retention
The Investigator agrees to keep the records stipulated in Section 15.1 and those documents that 
include (but are not limited to) the study -specific docum ents, the i dentificat ion log of all 
participat ing subjects, medical records, temporary media such as thermal sensit ive paper, source 
worksheets, all original signed and dated informed consent forms, subject authorizat ion forms 
regarding the use of pers onal health information (if separate from the informed consent forms), 
electroni c copy  of CRFs, including the audit trail, and detailed records of drug disposit ion to 
enable evaluat ions or audits from regulatory  authori ties, the Sponsor or its designees. A ny source 
docum entati on printed on degradable thermal sensitive paper should be photocopied by the site 
and filed wit h the original in the subject’s chart to ensure long -term legibilit y. Furthermore, ICH 
E6 [R2] Section 4.9.5 requires the Invest igator to r etain essent ial documents specified in ICH E6 
[R2] (Section 8) until at least 2 y ears after the last approval of a market ing applicat ion for a 
Mobocertinib
Study No. TAK -788-1008 Page 69of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALspecified drug indicat ion being investigated or, if an applicat ion is not approved, until at least 
2years after the investigation is discont inued and regulatory  authori ties are notified. In addit ion, 
ICH E6 [R2] Section 4.9.5 states that the study records should be retained unt il an amount of time 
specified by applicable regulatory  requi rements or for a time specifi ed in the Clinical Study  Site 
Agreement between the Invest igator and Sponsor.
Refer to the Clinical Study  Site Agreement for the Sponsor’s requirements on record retention. 
The Investigator and the head of the institution should contact and receive written approval  from 
the Sponsor before disposing of any  such docum ents.
Mobocertinib
Study No. TAK -788-1008 Page 70of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIAL16.0 REFERENCES
1.European Medicines Agency Committee for Medicinal Products for Human Use: Guideline on 
the Eval uation on the Pharmacokinetics of Medicinal Products in Patients with Impaired 
Hepa tic Funct ion, February , 2005.
2.Mansfield AS. The effect of hepat ic impairment on outcom es in phase 1 clinical trials in cancer 
subjects. Clin. Cancer Res. 2016;22(22):5472 -5479.
3.National Cancer Inst itute, Commo n Termino logy Cri teria for Adverse Events (CTCA E), 
Revised: Nov -2017 (v5.0). Available at: 
https://ctep.cancer.gov/protocoldevelopment/electronic_applicat ions/docs/CTCAE_v5_Quick
_Reference_8.5x11.pdf.
4.Rodi ghiero V. Effects of liver disease on pharmacokinet ics. An update. Clin Pharmacokinet 
1999;37(5):3 99-431.
5.Mobocertinib . Millennium Pharmaceut icals, Inc. Glo bal Invest igator Brochure. Edit ion 4.0, 
04January 2020.
6. U.S. Department of Health and Human Services, Food and Drug Administration, Center for 
Drug Eval uation and Research (CDER), Center for Biologics Evaluat ion and Research 
(CBER). Guidance for Industry. Pharmacokinet ics in Pat ients with Impaired Hepatic Funct ion 
—Study  Design, Data Analysis, and Impact on Dosing and Labeling. May  2003.
7.Verbeeck RK. Pharmacokinet ics and dosage adjustment in patients with hepatic dy sfunct ion. 
Eur J Clin Pharmaco l 2008;64(12):1147 -61.
Mobocertinib
Study No. TAK -788-1008 Page 71of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIAL17.0 APPENDICES
Appendix AResponsibilities of the Investigator
Clinical research studies sponsored by  the Sponsor are subject to ICH GCP and all the app licable 
local laws and regulat ions. The responsibilit ies imposed on Invest igators by the FDA are 
summarized in the “Statement of Invest igator” (Form FDA 1572), which must be completed and 
signed before the Invest igator may participate in this study.
The In vestigator agrees to assume the following responsibilit ies by signing a Form FDA 1572:
1.Conduct the study  in accordance wit h the protocol.
2.Personally conduct or supervise the staff that will assist in the protocol.
3.If the Investigator/inst itution retains th e services of any  individual  or party  to perform  
study -related duti es and funct ions, the Invest igator/inst itution shoul d ensure that this 
individual or party  is qualified to perform those study -related duti es and functi ons and shoul d 
implement procedures t o ensure the integrity  of the study -related duti es and funct ions 
perform ed and any  data generated.
4.Ensure that study  related procedures, including study  specific (nonrouti ne/nonstandard panel) 
screening assessments are NOT performed on potent ial subjects, prior to the receipt of written 
approval  from relevant governing bodies/authorit ies.
5.Ensure that all co lleagues and emplo yees assist ing in the conduct of the study are informed of 
these obligat ions.
6.Secure prior approval o f the study and any changes by an appropriate IRB/IEC that conform to 
21 CFR Part 56, ICH, and local regulatory  requi rements.
7.Ensure that the IRB/IEC will be responsible for init ial review, continuing review, and approva l 
of the protocol. Promptly report to the IRB/IEC all changes in resea rch act ivity and all 
anticipated risks to subjects. Make at least y early reports on the progress of the study  to the 
IRB/IEC, and issue a final report within 3 months of study  com pletion.
8. Ensure that requirements for informed consent, as outlined in 21 CFR Part 50, ICH and local 
regul ations, are m et.
9.Obtain valid informed consent from each subject who participates in the study , and docum ent 
the date of consent in the subject’s medical chart. Valid informed consent is the most current 
versio n approved by the IRB/IEC. Each informed consent form should contain a subject 
authori zation sect ion that describes the uses and disclosures of a subject’s personal 
inform ation (including personal health informat ion) that will take place in connect ion wit h the 
study . If aninformed consent form does not include such a subject authorization, then the 
Invest igator must obtain a separate subject authorization form from each subject or the 
subject’s legally acceptable representative.
10.Prepare and maintain adequate case histories of all persons entered into the study , incl uding 
CRFs, hospital records, laboratory  resul ts, etc, and maintain these data for a minimum of 
Mobocertinib
Study No. TAK -788-1008 Page 72of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIAL2years fo llowing notificat ion by the Sponsor that all invest igations have been discont inued or 
that the regulatory  authori ty has approved the marketing applicat ion. The Invest igator should 
contact and receive written approval fro m the Sponsor before disposing o f any such 
docum ents.
11.Allow possible inspection and copying by the regulatory  authori ty of GCP -specified essen tial 
docum ents.
12.Maintain current records of the receipt, administratio n, and disposit ion of Sponsor -supplied 
drugs, and return all unused Sponsor -supplied drugs to the Sponsor. 
13.Report adverse reactions to the Sponsor promptly. In the event of an SAE, notify the Sponsor 
within 24 hours.
Mobocertinib
Study No. TAK -788-1008 Page 73of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALAppendix BElements of the Subject Informed Consent
In seeking informed consent, the fo llowing information shall be provided to each subject:
1.A statement that the study  involves research.
2. A n explanat ion of the purposes of the research.
3.The expected duration of the subject’s participat ion.
4.A descript ion of the procedures to be fo llowed, including invasive procedures.
5.The i dentificat ion of any  procedures that are experimental.
6.The est imated nu mber of subjects invo lved in the study .
7.A descript ion of the subject’s responsibilit ies.
8.A descript ion of the conduct of the study .
9.A statement describing the treatment(s) and the probabilit y for random  assignment to each 
treatm ent.
10.A descript ion of the po ssible side effects of the treatment that the subject may receive.
11.A descript ion of any  reasonably  foreseeable ri sks or di scomf orts to the subject and, when 
applicable, to an embry o, fetus, or nursing infant.
12.A descript ion of any  benefi ts to the subject or to others that reasonably may be expected fro m 
the research. When there is no intended clinical benefit to the subject, the subject should be 
made aware of this.
13.Disclosures o f appropriate alternat ive procedures or courses of treatment, if any, that might be 
advantageous to the subject and their important potent ial risks and benefits.
14.A statement describing the extent to which confident iality of records i dentifying the subject 
will be maintained, and a note of the possibilit y that regul atory  agencies, audi tor(s), IRB/IEC, 
and the monitor may inspect the records. By  signing a written informed consent form, the 
subject or the subject’s legally acceptable representative is authorizing such access.
15.For research invo lving more than minimal risk, an explanat ion as to whether any co mpensatio n 
and an explanat ion as to whether any  medical treatments are available if injury  occurs and, if 
so, what they  consist of or where further informat ion may be obtained.
16.The ant icipated prorated payment(s), if any, to the subject for parti cipat ing in the study.
17.The ant icipated expenses, if any , to the subject for parti cipat ing in the study.
18.An explanat ion of whom to contact for answers to pertinent questions about the research 
(Invest igator), subject’s rights, and IRB/IEC and who m to contact i n the event of a 
research -related inj ury to the subject.
19.A statement that participation is vo luntary, that refusal to participate will invo lve no penalt y or 
loss of benefit s to whi ch the subject otherwise is ent itled, and that the subject or th e subject’s 
Mobocertinib
Study No. TAK -788-1008 Page 74of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALlegally acceptable representative may discont inue participat ion at any  time wi thout penal ty or 
loss of benefit s to whi ch the subject is otherwise ent itled.
20.The consequences of a subject’s decisio n to wi thdraw from  the research and procedures fo r 
orderly terminat ion of part icipation by the subject.
21.A statement that the subject or the subject’s legally acceptable representative will be informed 
in a timely  manner if informat ion beco mes available that may be relevant to the subject’s 
willingness to continue participat ion in the study .
22.A statement that results of PGx analysis will not be disclosed to an individual, unless 
prevailing laws require the Sponsor to do so.
23.The foreseeable circumstances or reasons under which the subject’s participat ion in the study  
may be terminated.
24.A wr itten subject authorization (eit her contained within the informed consent form or provided 
as a separate document) describing to the subject the contemplated and permissible uses and 
disclosures of the subject’s personal in formation (including personal health informat ion) for 
purposes of conduct ing the study. The subject authorizat ion must contain the fo llowing 
statements regarding the uses and disclosures of the subject’s personal informat ion:
a)that personal information (including personal healt h informat ion) may be processed by  or 
transferred to other parties in other countries for clinical research and safet y reporti ng 
purposes, including, without limitat ion, to the fo llowing: (1) Takeda, its affiliates, and 
licensing p artners; (2) business partners assist ing Takeda, its affiliates, and licensing 
partners; (3) regulatory  agencies and other healt h authorities; and (4) IRBs/IECs;
b)it is possible that personal informat ion (including personal healt h informat ion) may be 
proces sed and transferred to countries that do not have data protection laws that offer 
subjects the same level o f protecti on as the data protection laws wit hin this country; 
however, Takeda will make every  effort to keep y our personal  information confident ial, 
and y our name will not be di sclosed outsi de the clinic unless required by law;
c)that personal information (including personal healt h informat ion) may be added to 
Takeda’s research databases for purposes of developing a better understanding of the 
safet y andeffect iveness o f the study  medicat ion(s), studying other therapies for patients, 
developing a better understanding of disease, and improving the efficiency of future 
clinical studies;
d)that subjects agree not to restrict the use and disclo sure of their per sonal informat ion 
(including personal healt h informat ion) upon withdrawal fro m the study  to the extent that 
the restricted use or disclosure of such informat ion may  impact the scient ific integrity of 
the research; and
e)that the subject’s ident ity will remai n confident ial in the event that study  resul ts are 
published.
Mobocertinib
Study No. TAK -788-1008 Page 75of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIAL25.Female subjects of childbearing potential (eg, nonsterilized, premenopausal female subjects) 
who are sexually  active m ust use highly  effect ive contraception (as defined in the informed 
consent) from signing the informed consent and throughout the duration of the study, and for at 
least 30 day s after the dose of study  drug. Regul ar pregnancy tests will be performed 
throughout the study for all female subjects of childbearing potential. If a subjec t is found to be 
pregnant during study , study  drug will be discont inued and the Invest igator will o ffer the 
subject the cho ice to receive unblinded treatment informat ion. 
26.Male subjects must use highly effect ive contraceptio n (as defined in the informed co nsent) 
from signing the informed consent throughout the duration of the study and for at least 30 days 
after the dose of study drug. If the partner or wife of the subject is found to be pregnant during 
the study , the Invest igator will o ffer the subject the choice to receive unblinded treatment 
inform ation. 
27.A statement that clinical study  informat ion from this study  will be publicly disclo sed in a 
publicly  accessible website, such as ClinicalTrials.gov.
Mobocertinib
Study No. TAK -788-1008 Page 76of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALAppendix CInvestigator Consent to the Use of Personal Information 
Takeda will co llect and retain personal information of Invest igator, including his or her name, 
address, and other personally identifiable informat ion. In addit ion, Invest igator’s personal 
inform ation may be tra nsferred to other parties located in countries throughout the world (eg, the 
United Kingdom, United States, and Japan), including the following:
Takeda, its affiliates, and licensing partners.
Business partners assist ing Takeda, its affiliates, and licensi ng partners.
Regulatory  agencies and other health authorit ies.
IRBs and IECs.
Invest igator’s personal informat ion may be retained, processed, and transferred by  Takeda and 
these other parties for research purposes including the fo llowing:
Assessment of the suitabilit y of Invest igator for the study  and/or other clinical studies.
Management, monitoring, inspect ion, and audit of the study .
Analysis, review, and verificat ion of the study  results.
Safety reporti ng and pharmacovigilance relat ing to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies rel ating to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies relat ing to other me dicati ons used in other clinical studies that may contain 
the sam e chemical com pound present in the study  medicat ion.
Inspect ions and invest igations by regulatory  authorit ies relat ing to the study.
Self-inspect ion and internal audit within Takeda, its affiliates, and licensing partners.
Archiving and audit of study  records.
Posting Invest igator site contact informat ion, study details and results on publicly accessible 
clinical study  registri es, databases, and websites.
Invest igator’s personal informat ion may be transferred to other countries that do not have data 
protecti on laws that offer the same level of protection as data protection laws in Invest igator’s own 
country .
Invest igator acknowledges and consents to the use of his or her personal information by Takeda 
and other parties for the purposes described above.
Mobocertinib
Study No. TAK -788-1008 Page 77of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALAppendix DPregnancy and Contraception
Contraception and Pregnancy Avoidance Procedure
Mobocertinib may pose a risk to developing fetuses or to babies who are bein g breastfed. Because 
mobocertinib may affect an unborn baby, female participants should not become pregnant while in 
this study , and male parti cipants shoul d not conceive wi th their female partner(s) while in this 
study . Women who are pregnant or breastfee ding will  not be allowed to take part in this study .
Women of childbearing potential and male pat ients must use m edically  acceptable bi rth control . 
Avoiding sexual act ivity is the only certain way  to prevent pregnancy . 
Males Subjects and Their Female Part ners:
It is not known whether the study medicat ion will affect sperm or an unborn baby. Based on anima l 
studi es, taking mobocertinib may lead to testi cular changes that could impact reproduction. For 
this reason, to be in the study  males m ust agree not to father a child or donate sperm during the 
study  and f or at l east 30 day safter mobocertinib dosing. 
If a male has not had a vasecto my and are sexually active with any  person who i s pregnant, or 
could get pregnant, he m ust use a condom wit h spermicidal cream or jelly  each time he has sex 
during the study and for at least 30 days after mobocertinib dosing. If a male is surgically steril ized 
(ie, have had a vasectomy ) he m ust agree to use an appropriate method of barrier contraception 
(latex condom wit h a spermicidal agent) during the entire study , and for at l east 30 days after 
mobocertinib dosing. Or, he should co mpletely avoid having h eterosexual  intercourse.
If a female partner does become pregnant while a male subject is taking part in the study , the 
subject must tell the study  doctor immediately .
In this situation, the female partner should be under medical supervisio n during her pre gnancy, and 
the baby should be under supervisio n after it is born. The female partner may be asked to give her 
consent to the collection of informat ion related to both herself as well as the baby.
Acceptable birth control for males with female partners inc ludes any o f the following:
total abst inence (no sexual intercourse) if it agrees with his preferred and usual lifest yle.
a barri er method ( latex condom wit h a spermicidal agent).
Males must use acceptable birth control during the study  treatm ent peri od an d for at l east 30 day s 
after mobocertinib dosing and shoul d tell their femal e partner(s) that they  are in research study .
Females:
Females must agree not to beco me pregnant, breastfeed a baby or donate an egg or eggs (ova) 
during the study  and for at least 30 days after mobocertinib dosing. Wom en of childbearing 
potenti al must use acceptabl e birth control  from the time of signing the informed consent form 
until at least 30 days after mobocertinib dosing.
If a female has been surgically sterilized or is post menopausal, she does not need to meet any  
contraception requirements to take part in this study. If a female is o f childbearing potential and is 
Mobocertinib
Study No. TAK -788-1008 Page 78of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALsexually  active wit h a m ale partner, she must be willing to use an acceptable method of 
contraception during th e study  and f or at l east 30 days after mobocertinib dosing.
Mobocertinib may decrease effectiveness of hormonal contraceptives, therefore, women of 
childbearing potential must use effective contraception without hormones. Acceptable birth 
control  for wom enof childbearing potential with male partners must include one form of highly  
effect ive non -horm onal contracepti on and one additi onal effect ive (barrier) method, as described 
below:
Highly effective non -hormonal methods Additional effective (barrier) metho ds 
Non-hormo nal intrauterine device Male or female condom with or without spermicide 
(female and male condoms should not be used together)Vasectomised sole sexual partner (removal of the tube 
that carries sperm from the testicle to the penis)
Sexual abstinence (no sexual intercourse) Cap, diaphragm or sponge with spermicide
Total  abstinence (no sexual intercourse) may be considered an acceptable method of birth control 
if it agrees wi th her preferred and usual lifestyle. 
In order to enter the study , all females must have a pregnancy  test to confirm  that she is not 
pregnant . This test will be repeated just before she starts taking the study  medicat ion and at 
check -in. If a pregnancy test during the study shows that she may bepregnant , she will be 
withdrawn from  the study and the treatment will end. She will be asked for the results of any tests 
and procedures carried out during pregnancy and up to the birth. She may also be asked for the 
resul ts from any evaluat ion of the baby after the birth.
Mobocertinib
Study No. TAK -788-1008 Page 79of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALAppendix EDetailed Description of Amendments to Text: Amendment 1
Change 1 . The criterion 17 of exclusio n for hepatic impairment subjects should be an inclusio n 
criterion for the sam e group of subjects. 
Move cri terion 17 in Sect ion  7.2.2 –Exclusio n Criteri a for Hepatic Im pairment Subjects to 
beco me criterion 6 in Sect ion  7.1.2 –Inclusio n Criteri a for Hepatic Im pairment Subjects and 
updating in the corresponding places in Sect ion 1.0 – Study  Summary  
Moved 
Wording 
and 
Reworded:Diagnosis of chronic (eg, imaging, biopsy, etc.) s table hepat ic insufficiency for at 
least 6 m onths (no acute episodes of illness within the previous 2 months due to 
deteri oration in hepatic funct ion) wi th features of cirrhosis due to any  etiology 
according to medical history .
Change 2. The exclusio n criterion 12 of Sect ion 7.2.2 -Exclusio n Criteria for Hepatic Impairment 
Subjects allows for hepat ic impairment subjects to be hepat itis B posit ive if the viral t iter is below 
1000 copi es/mL o f plasma at the time of testing and therefore sh ould be harm onized wi th test 
HBsAg under “ Other” in Section 9.2.9.1 -Clinical Laboratory  Tests. 
The Section 9.2.9.1 -Clinical Laboratory  Tests, “ Other ” test HBs Ag
Added 
Wording(if HI pati ents are posi tive for HBV, DNA copies are below 1000 copies/mL in 
plasma)
Change 3 . Scheduling coagulat ion at the same t ime as the other clinical laboratory  tests 
throughout the study .
Coagulation as a clinical laboratory test was missing from the Section 1.0-The Schedule of Study 
Procedures.
Wording 
AddedAdd “Coag” to the row with “Hem, Serum Chem  k, and UA” and add the definit ion 
of the abbreviat ion to the list of abbreviat ions below Coag = Coagulat ion.
Mobocertinib
Study No. TAK -788-1008 Page 80of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALAppendix FDetailed Description of Amendments to Text: Amendment 2
Change 1 . Due to the COVID -19 pandemic of 2020, the mandatory  measurement of the PFT was 
removed from  the protocol to diminish the risk of airborne virus transmissio nduring the study  
conduct. 
The fo llowing sect ions were updated to reflect this change:
Removal of Criteria 6 and 8 in Section  1.0–Study Summary (Inclusi on Criteria), 
Removal of the PFT associated footnote “j” in Sect ion  3.0–Schedule o f Study Procedures, 
Removal of reference to PFT in Sect ion4.4–Benefit/Risk Profile ,
Removal of reference to the PFT in Secti on  5.3.3 –Study  Desi gn, 
Removal of Criterion 6 i n Sect ion  7.1.1 –Inclusion Criteria for Healthy Subjects, 
Removal of Criterion 8 i n Sect ion7.1.2 -Inclusio n Cri teria for Hepati c Impairment 
Subjects, 
Removal of details o f the PFT in Sect ion9.2.6 .1–Pulmo nary Function Test,
Removal of abbreviat ions FEV1 and FVC in Sect ion  14.1.4 –List of Abbreviat ions.
Removed 
Wording:Pulmo nary Function Test (PFT) (spirometry  only) is requi red to be perform ed 
and be assessed as normal at screening. Post -dose PFTs will be performed only if 
indicated on the basis o f pulmo nary symptom s at the discret ion of the 
Invest igator or designee (Secti on  1.0and Sect ion  6.0).
Criterion 6 ( Section 1.0and Section 7.1.1 ) -Normal baseline spiro metry for FVC 
and FEV1/FVC wit hin 7 days pri or to dosing based on the fo llowing normal FVC 
and FEV1/FVC range:
18 -39 years of age: ≥80% of predicted normal
40 -59 years of age: ≥75% of predicted normal
60 -<80 years of age: ≥70% of predi cted norm al
Criterion 8 (Section  1.0and Sect ion7.1.2 )-Normal baseline spiro metry  for FVC 
and FEV1/FVC wit hin 7 days prior to dosing based on the fo llowing norm al
FVC and FEV1/FVC range:
18 -39 years of age: ≥80% of predicted normal
40 -59 years of age: ≥75% of predicted normal
60 -<80 years of age: ≥70% of predi cted norm al
Pulmo nary Function Test associated footnote “j ” –“To be conducted within 
7days prior to dosing (Secti on  3.0).”
Mobocertinib
Study No. TAK -788-1008 Page 81of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALSpirometry measures will be taken at screening (wit hin 7 days prior to dosing) 
using a standard calibrated spiro meter to determine the parameters detailed 
below. Spirometry  may be repeated during the study  in response to pulmonary  
symptoms at the discretion of the Invest igator or designee.
FEV1 (forced expiratory  volume);
FVC (forced vi tal capaci ty);
FEV1/FVC.
FEV 1Forced expiratory  volume
FVC Forced vial capacit y(Secti on 9.2.6.1)
Secti on  1.0–Study  Summary , Secti on  3.0–Schedul e of Study  Procedures (addi tional footnote 
“k”), and Sect ion9.2.6 .1–Pulmo nary Funct ion Test.
Addit ion of 
wordingSpirometry as the pulmo nary function test (PFT) may be performed in the event 
of a pulm onary adverse event (AE), if deemed clinically necessary  by the 
Invest igator or designee.
Secti on  3.0–Schedule of Study  Procedures –row for pulmo nary functi on test (this test is 
perform ed in response to AEs only ).
Merging 
columnsThecolumns fro m screening unt il Day 10 were merged and indicated with a 
single X.
Change 2. The reference to more than two specific metabo lites for the PK analysis was removed 
and only  the two known m etabo lites (AP32960 and AP32914) will be assessed in subjects wi th 
moderate and/or severe hepat ic impairment (HI) compared to matched -healt hy subjects wi th 
norm al hepatic funct ion. The fo llowing sect ions were updated to reflect this change:
Secti on  1.0–Study  Summary , 
Secti on  3.0-Schedule of Study  Procedures, 
Secti on  6.1Study  Design, 
Secti on  6.2-Dose Escalat ion, 
Secti on  6.3.5 -Critical Procedure s Based on Study Object ives: Timing of Procedures, 
Secti on  9.3.1.1 -Plasma PK Measurements, 
Secti on11.1.3 -Pharmacokinet ic Analysis, 
Secti on  11.2 -Interim Analysis and Criteria for Early Terminat ion.
Removed 
Wording “including but not limited to”
Mobocertinib
Study No. TAK -788-1008 Page 82of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALChange 3. Due to the COVID- 19 pandemic, all return visit s on study  were updated to full
confinement. The fo llowing sect ions were updated to reflect this change:
Secti on  1.0–Study  Summary , 
Table 1.a–Study  Design, 
Secti on  2.0–Study  Schemat ic, 
Secti on  3.0Schedule of Study  Procedures, 
Secti on  6.1-Study  Design, 
Table 6.b-Study  Design .
Secti on  9.3.4 -Confinement
Wording 
updateThe wording was updated as appropriate for confinement up to Day  10
Flow Chart 
UpdatedRemoval of “X” for Day  8 and 10 return visits and col umns fro mDay -1 to 
Day 10merged and indicated with a single X for fullconfinement.
Wording 
updateReference to verbiage for return visits and/or returns to CRU are removed since 
there are no more return visits, in the appropriate protocol sect ions.
Change 4. Section 1.0–Study  Summary  and In Secti ons  7.1.2 and 7.2.1 , the title of the inclusio n 
and exclusio n was updated for specificit y in relation to hepatic subject participation in.
Wording 
updateFrom  “Hepat ic Impairment Subjects” to “Subjects with Moderate or Severe 
Hepati c Impairment”
Change 5. In Section 9.2.9.1 -Clinical Laboratory Tests: COVID -19 testing was added
A caveat for positive results for COVID -19 testing at screening or check -in has been added as an 
exclusio n criterion to Section 1.0(Study  Summary, Excl usion Criteria), Secti on  7.2.1 (Excl usion 
Criteria for He althy Subjects), and Section  7.2.2 (Exclusio n Cri teria for Hepati c Impairment 
Subjects).
Addit ion of 
wordingExclusio n Cri terion 10 (Heal thy Subjects) and Cri terion11 (Subjects with 
Moderate or Severe Hepatic Impairment) – “Posi tive results for COVID -19 
testing at screening or check -in.”
Change 6 .In Section 4.0(Introduction), wording was updated to match the current IB and the 
study  TAK -788-1007
Wording 
updateUpdated From IB Edi tion 3.0, Jan -2019 to IB Edi tion 4.0, 04 -Jan-2020 and the 
background informat ion has been updated.
Mobocertinib
Study No. TAK -788-1008 Page 83of 83
Protocol Incorporating Amendment No. 02 07 August 2020
CONFIDENTIALChange 7.The name of the study drug was changed fro m TAK -788 to mobocertinib. 
Change 8. In Section 9.2.4 –Vital Signs, the rest period before taking vital signs was added to the 
text.
Wording 
Added (subjects must be seated for at least 5 minutes prior to measurement.)
Change 9. In Section 9.2.5 - 12- Lead ECG, the rest period duration for ECG measurement was 
added. 
Wording 
Adding Subjects are required to be supine for at least 5 minut es prior to the ECG 
measurement.
Change 10 .In Section 4.4–Benefit/risk profile, the TEAEs and safet y info rmation was updated in 
accordance with the new IB.
Change 11.In addition to the aforementioned changes, minor updates were made throughout th e 
protocol  for grammar and formatting.
    
 
  
 
  
 
ELECTRONIC SIGNATURES  
Signed by Meaning of Signature Server Date 
(dd-MMM-yyyy HH:mm ‘UTC’) 
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
 
090101d680e27429Phase 1 Pharmacokinetics and Safety Study of Oral Mobocertinib in Subjects with Moderate or Severe Hepatic
Impairment and Normal Hepatic Function
Clinical Science Approval 11-Aug-2020 14:06 UTC
Clinical Pharmacology Approval 11-Aug-2020 20:30 UTC
Biostatistics Approval 12-Aug-2020 01:01 UTC
